Though we associate chilly fall temperatures with flu season, the two are not mutually inclusive.The time in which the flu virus is most contagious is widely known as the "season," and though that time of year usually starts in October and peaks from December to February, flu deaths have already been reported in the United States. While it remains difficult to predict how severe this season will be, it's not too late to create a plan of attack.

Dr. Nodar James, medical director at Upper East Side Rehabilitation and Nursing Center, told Salon that because flu symptoms can develop days after the virus enters the body, it's possible to spread the flu to someone else before know you are sick, as well as while you are sick.

"The flu is spread in a few different ways.One way is through contact with bodily fluid, so if someone with the flu coughs or sneezes and doesn't cover their mouth or nose, anyone who comes in contact is at risk of getting sick," James explained."Most people are most contagious 34 days after the flu begins. However, in some cases you can also infect people even before symptoms begin."

Here are some tips on how to prepare for the flu season.

Get your flu vaccine.

The best way to protect against serious outcomes of the flu virus is to get vaccinated,according to nearly every medical professional or health care expert Salon spoke with for this article.

The effectiveness of the influenza vaccine, which combines four different inactive flu strains, varies from person to person. Recent studies show that flu vaccination reduces the risk of flu illness between 40% and 60% of people.

The flu vaccine is not perfect, mostly because of the number of strains of the virus that circulate, but it can provide some cover. Because flu virus strains evolve every year, medical experts recommend getting vaccinated annually.

Nasal spray is also an option for patients who are needle-averse. In previous years, the American Academy of Pediatrics recommended children be vaccinated with a shot, as some studies showed it was more effective. There is no such suggestion this year.

Wash your hands.

TheCenters for Disease Control and Prevention (CDC)recommends washing your hands frequently and for at least 20 seconds at a time (perhaps sing the "Happy Birthday" song from beginning to end.) When washing your hands, "be sure to lather the backs of your hands, between the fingers, and under your nails," the CDC notes.

"People are more germ-conscious these days so avoiding a handshake is not as rude as once thought, especially during flu season. If you must do it,washor sanitize with yourhands immediately,"Dr. Benjamin Barlow, chief medical officer of American Family Care, told Salon.

Keep your distance.

It's easy to spread germs whenliving in close quarters, especially during the winter months when more people tend to stay indoors. However, doctors recommend avoiding close contact and sharing during the season.

"Since viruses like the flu spread through droplets secreted through coughing, sneezing and breathing, spending hours in close proximity to a person who is sick, breathing in the droplets, is a sure-fire way to get sick,"Dr. Anna Cabeca, a physician and author of "The Hormone Fix" told Salon. "A good combo is to regularly wash your hands, carry a scarf when traveling and perhaps to wear a face mask, especially if you are susceptible, or if you're sick yourself and don't want to contaminate others."

Get enough sleep.

Sleep is critical to maintaining and strengthening our immune system, which is constantly working to quash various kinds of viruses and bacteria. During flu season, doctors advise making sleep a priority and trying to get the recommended 8 hours of sleep each night.

Reduce stress levels.

Relieving stress and anxiety levels is key to increasing your overall health and sense of well-being.Dr. Steve Silvestro, a pediatrician in the Washington, D.C., area and the host of The Child Repair Guide Podcast, said managing mental stress is "one of thebest ways to keep healthy during flu season."

"It has to do with the effects of cortisol on our immune system," he explained to Salon. "We know that a short burst of cortisol say, going on a short run can help the immune system by briefly decreasing inflammation. But when cortisol is chronically elevated, like when we are feeling stressed at work or home for long stretches of time, inflammation in our bodies increases, and our immune system has a harder time fighting off infection."

In that way, taking care of your metal health perhaps by doing something you love, such as spending time in nature can help your immune system stay strong.

Read the original:
We asked experts how to dodge the flu this year - Salon

Recommendation and review posted by Bethany Smith

Can leftover spaghetti really kill you? Can you actually cough up a blood clot in the shape of your lung? In Yahoo Lifestyle Canadas newest series, What The Health?!, we ask doctors to weigh in on odd health news stories and set the record straight. Be sure to check back every Friday for the latest.

A Sudbury, Ont. woman who spent years in tears as her nose, chin, hands and feet gradually kept getting bigger was shocked to learn that changes to her physical features were caused by a brain tumour.

Rebecca Churan says she couldnt understand why she was inexplicably getting uglier as her jawline and chin continued to grow and her feet went from size 8.5 to 10.

ALSO SEE: Saskatchewan curler dies from rare childbirth condition: What is amniotic fluid embolism?

Over the span of at least a decade, doctors diagnosed the now 29-year-old with a range of conditions including borderline diabetes, polycystic ovary syndrome, anxiety and depression. As her body kept changing, Churan became increasingly desperate for help, visiting another physician earlier this year.

I told this doctor that my face was changing, and I was getting uglier, and that I didn't understand why I was gaining weight since I was barely eating, Churantoldthe Daily Mail. She issued me a blood test and then called me back in and told me I had a pituitary tumour based on the results of that test.

That test measured insulin-like growth factor, or IGF1, which controls tissue and bone growth. Depending on a persons age, a typical reading ranges from 97 to 297; Churans was 1015. Further examination found that she had a benign tumour in her brain on her pituitary gland, which releases hormones that control human growth.

It causedacromegaly, a rare condition in which the body produces excessive amounts of the growth hormone, causing body parts to become abnormally large. The condition gets its name from the Greek words for extremities and enlargement.

When acromegaly begins in childhood, it can lead to giantism, as seen in Andr the Giant and the late actor Richard Kiel, who played the steel-tooth villain Jaws in two James Bond films. When it develops after someone has reached their full height and their bones are already fused, different parts of the body will being to grow and tissue becomes thicker, says DrAli Imran, a professor of medicine in the division of endocrinology at Dalhousie University.

ALSO SEE: What The Health?! British teenager paralyzed after falling from his couch

Acromegaly affects approximately three to five people in a million, with about 2,000 Canadians living with the condition. However, those numbers are likely low.

Many people remain, unfortunately, undiagnosed forever, Imran tells Yahoo Canada. The actual prevalence of disease is much higher what is currently being reported.

The reason is that many of the features of acromegaly are very nonspecific, and others are slow to develop, he explains. For instance, one common feature is the hands and feet begin to enlarge and the facial features begin to enlarge, but the change is so subtle and so slow, it may take many years before somebody notices. If a doctor has not seen a patient for a number of years they can see the difference, but on a day to day level the difference is very hard to notice until it becomes really obvious. Many of the other features like excessive sweating, weight gain, aching joints, and sleep apnea are so common in the general population that most people wont put two and two together. As a result, diagnoses can be delayed from up to 10 years or even more.

ALSO SEE: What The Health?! Woman's ruptured brain cyst originally misdiagnosed as migraines

Other symptoms include skin tags, enlarged tongue, deepening of voice due to enlarged sinuses and vocal cords, headaches, impaired vision, decreased libido, abnormalities in menstrual cycle and erectile dysfunction.

Overgrowth of bone and cartilage can lead to arthritis, while thickening tissue can cause carpal tunnel syndrome. Even organs, including the heart, can enlarge.

Story continues

The most common treatment is surgery to remove the tumour, with the pituitary gland reached through an incision in the noise or upper lip. Sometimes, unfortunately, not all of the tumour can be excised; they can also recur. Radiation and medications are other options, though Imran notes that drugs are expensivein some cases, up to several thousands of dollars a month.

Churan had her tumour removed through her nose. Her hands, feet, and facial features shrunk down to a normal size within months.

Shes going public with her story to raise awareness of acromegaly and encourage people who may be having similar symptoms without explanation to seek medical help. The Canadian Pituitary Patient Association has marked November 1 asAcromegaly Awareness Day.

ALSO SEE: What the Health?! Can you really die from burning your throat on hot foods?

There really is no information other than extreme cases online, Churan said. There's barely any awareness or tools to help people recognize the signs, so many cases are diagnosed as hormonal disorders. I saw the scariest photos of Andr the Giant and others who had not been treated early on during the process. I was mortified, scared, and hopeless.

I had this tumour for over 15 years based on the photos I've looked back over, but I just thought it was the way I was ageing at the time, she said. You must stay positive and find hope in any way you can while fighting. I want people to understand that a simple blood test can often diagnose a pituitary tumour. Dont just accept any diagnosis without digging deeper and asking if something else could be causing it.

Besides the physical effects of the condition, theres the severe mental and emotional toll it can take.

Churan post surgery. Image via Facebook.

What is important is for people to understand is that these rare disorders can be devastating for the people who suffer from them, Imran says, urging people with acromegaly to seek specialist care, such as that available in Nova Scotia. Caregivers and the public need to know how these affect the lives of a small number of people in a very bad way. The major problem which we find is chronic pain, ongoing arthritis, and nerve problems. Even after treatment, many dont feel better.

The psychological impact is just immense, he adds. People who have gone through a lot of health issues end up very frustrated that they havent been able to find an answer and realize their condition was missed for 10 or 15 years and sadly they have to live with this for years. This is not an easy problem; theres no easy fix, but were fortunate to be living in a country where treatment is available.

Let us know what you think by commenting below and tweeting @YahooStyleCA! Follow us on Twitter and Instagram.

Read the original:
What The Health? Brain tumour causes woman's nose, chin to grow - Yahoo News Canada

Recommendation and review posted by Bethany Smith

A committee for the US Food and Drug Administration now recommends that the approval of Makena, a drug used to reduce the risk of preterm births, should be withdrawn and some women who have used the medication are sounding the alarm.

The 9-7 vote, which took place at a meeting of the Bone, Reproductive and Urologic Drugs Advisory Committee on Tuesday, came in response to evidence suggesting that the drug was not effective.

The committee serves as an advisory group to the FDA and the voting results are not binding, said Dr. Walid Gellad, director of the Center for Pharmaceutical Policy and Prescribing at the University of Pittsburgh, who was not involved in the committee meeting.

Most of the time the FDA will make a decision that aligns with the committee, but not always, Gellad said.

One study showed FDA will go against the committee about 20% of the time. But the committee did vote that removal of the drug from the market was warranted, which is relevant for supporting any FDA decision about withdrawal, he said.

An FDA spokesperson confirmed in an email on Thursday that the committee voted 13-3 that there is not substantial evidence of effectiveness of Makena in reducing the risk of recurrent preterm birth, based on findings from two trials that were part of a study called PROLONG, published last week in the American Journal of Perinatology.

Nine members of the committee voted to pursue withdrawal of approval for Makena, and seven members voted to leave Makena on the market under accelerated approval and require a new confirmatory trial.

None voted to leave the drug on the market without requiring a new confirmatory trial.

Makena, sold by AMAG Pharmaceuticals, is a progestin hormone that gets delivered to a patient as an injection. In 2011, the FDA approved the medicine to reduce the risk of preterm birth in women who have a history of spontaneous preterm birth under the provisions of accelerated approval regulations.

Accelerated approval is a mechanism for drugs to be approved by FDA before they have proven benefit. They need to address a high need clinical condition for which there are no or few other therapies, like premature birth, and they have to show some effect on a surrogate outcome an outcome that is reasonably expected to be related to clinical benefit, Gellad said.

As a requirement for a drug that is approved through accelerated approval, the company must perform a confirmatory trial to show clinical benefit. In this case, it took eight years, and the confirmatory trial showed no benefit, he said, adding that many of the patients in the trial were not from the United States.

So one argument from the company is that the trial does not represent effectiveness in the US, and because there are no other drugs available, and a prior study showed effectiveness, and its recommended by various OB/GYN groups, that it should stay on the market and be evaluated in another trial, he said. The caveat is that this treatment existed even before accelerated approval because pharmacies could compound or make the therapy themselves so if the drug leaves the market, there is still an option to use the drug.

Current guidelines in the United States recommend the use of progesterone supplementation, such as Makena, in women with prior spontaneous preterm births.

Last week, when the results of the PROLONG study were published, the Society for Maternal-Fetal Medicine released updated clinical guidance for providers to discuss important factors with patients, including uncertainty regarding the benefit of the drug.

Meanwhile, the American College of Obstetricians and Gynecologists released a statement from its Vice President for Practice Activities, Dr. Christopher Zahn, indicating that ACOGs clinical guidance on the use of the medication will remain in effect.

ACOGs guidance is based on a review of the best available literature. As such, we will continue to monitor this topic, evaluate additional literature and any further analyses as published, and address findings as needed in relevant clinical guidance, Zahn said in the statement.

Danielle Boyce, a mother of four and research consultant based in Philadelphia, had significant preterm labor issues with her first two children, including her eldest son, Charlie. He was born preterm at 34 weeks, developed a seizure disorder as a baby and now has Lennox-Gastaut syndrome, severe intellectual disability and autism, Boyce said.

When Boyce became pregnant for a third time at age 42, she was very concerned about having another preterm birth and made the shared decision with her physician to start using Makena. Her third and fourth children came home from the hospital and did not require a NICU stay. They are both healthy and developing normally, Boyce said.

I am glad that I had the opportunity to use Makena while it was still available because it worked for me, Boyce said in an email on Thursday.

Boyce added that she respects the decision the members of the FDA panel made since it was based on evidence presented to them but noted that studies can be flawed.

As someone trained in epidemiology and statistics, as well as someone who has served on FDA panels myself, I can appreciate the difficult decision that the panel had to make given the evidence presented, Boyce said.

I agree that the study design could have been better and the statistical endpoints were not achieved, she said about the evidence. However, this is a rare case where the stakes are so high and the side effect profile is so low that an additional layer of scrutiny is warranted beyond the statistical evidence presented before a decision is made to pull this effective medication from the market.

Boyce said that she would ask the FDA panel to consider ACOGs judgment.

Meanwhile, there also have been calls for the FDA to ban Makena.

Earlier this month, the consumer advocacy nonprofit Public Citizen submitted a petition to request that the FDA immediately withdraw the approval of all medications containing hydroxyprogesterone caproate (Makena).

Meena Aladdin, a health researcher at Public Citizens Health Research Group, testified during the FDA committee on Tuesday, arguing that maintaining approval of Makena in the absence of any clinical benefits being demonstrated by Trial 002 or Trial 003 would make a mockery of the more than 50-year FDA legal standard requiring substantial evidence of a drugs effectiveness.

In response to the FDA vote, AMAG Pharmaceuticals Chief Medical Officer Dr. Julie Krop said in a statement that the company was disappointed.

We are committed to working with the FDA to identify feasible ways to generate additional efficacy data on Makena while retaining current access to the therapy for at-risk pregnant women, Krop said in the statement.

For more than a decade, health care providers have relied on hydroxyprogesterone caproate (Makena) to reduce preterm delivery in high-risk patients, which aligns with recently updated treatment recommendations of the American College of Obstetricians and Gynecologists, as well as the Society for Maternal-Fetal Medicine, she said.

The medication now remains in limbo until the FDA makes a final decision based on its committees new recommendations.

I predict FDA will remove the drug from the market, since the confirmatory trial showed no benefit, and removing the drug does not necessarily completely eliminate the opportunity for some women to receive the therapy, Gellad said. There is an 80% chance I will be right.

Continued here:
FDA panel recommends withdrawing approval of Makena drug, used to prevent preterm births - KEYT

Recommendation and review posted by Bethany Smith

Share

Share

Share

Email

There is not any specific diet to treat melancholy , but ingesting more of some foods and less or none of others can help some people handle their symptoms.

In this guide, we look at a few foods and nutrients that may be valuable and a few that individuals must avoid.

Many nutrients are available to purchase, but their should be asked by people Because they may occasionally interfere with other medications, Physicians advice before using any supplements.

One factor that may contribute to depression is.

A 2017 research Found that people with moderate-to-severe depressions signs improved when they ate a much more healthful diet for 12 weeks and received nutritional counselling sessions.

The diet centered on whole and fresh foods that are high in Nutrients. It limited sweets, refined foods, and food, including junk food.

Depressive symptoms, including mood and anxiety, improved enough to achieve remission criteria in more than 32 percent of the participants.

The researchers reasoned that people could help manage by fixing their diet, or enhance their symptoms of depression.

Selenium

Some scientists have suggested that raising selenium intake may help improve mood and reduce stress, which might help to make depression more manageable.

Selenium is found in Many Different foods, including:

Entire grainsBrazil nutsa few fishorgan meats, such as liver.

Vitamin D

Vitamin D might help improve the symptoms of depression, according to a 2019 meta-analysis.

Individuals obtain most of their vitamin D through sun exposure, but dietary sources are also important.

Foods that can supply vitamin D comprise :

Fatty fishfortified dairy productsbeef liveregg

Omega-3 fatty acids

The results of some studies have suggested that omega-3 fatty acids might assist with depressive disorders.

On the other hand, the writers of a 2015 review concluded that more studies are required to confirm this.

Eating omega-3 fatty acids may reduce the risk of mood disorders and Brain diseases by preserving and improving brain function.

Good sources of omega-3 fatty acids include:

Cold-water fish, such as salmon, sardines, tuna, and salmonflaxseed, flaxseed oil, and chia seedswalnuts

Antioxidants

Vitamins A (beta carotene), C, and E contain substances called antioxidants.

Antioxidants help eliminate free radicals, which are.

If the body cant remove enough free radicals, oxidative stress may develop. Lots of health problems can result, which may include depression and stress.

The results of a 2012 research Suggested that swallowing the vitamins that provide antioxidants may reduce symptoms of anxiety in people with generalized anxiety disorder.

Fresh, plant based foods, like berries, are great sources of antioxidants. There is that A diet rich in fruits and vegetables, soy, along with other plant products might help reduce the stress-related symptoms of depression.

B vitamins

Vitamins B-12 and B-9 (folate, or folic acid) help protect And maintain the nervous system, including the brain. They may help reduce symptoms and the threat of mood disorders.

Sources of vitamin B-12 include:

Eggsmeatpoultryfishoystersmilkentire grainssome fortified cereals

Foods that contain folate include:

Dark leafy vegetablesfruit and fruit juicesnutslegumesentire grainsdairy productsmeat and poultryseafoodeggs

Zinc assists the body perceive flavor, but additionally, it boosts the immune system and might affect melancholy.

Some research have indicated that zinc levels might be lower in people with depression and that zinc supplementation might assist antidepressants operate more effectively.

Zinc is current in:

Whole grainsoysterssteak, chicken, and porkbeansnuts and pumpkin seeds

Protein

It might also help people, although protein allows the body repair and to raise.

The body uses a protein called tryptophan to create serotonin, thefeel good hormone.

Tryptophan is present in:

Tunaturkeychickpeas

Serotonin Seems to play a role In depression, but the mechanism is complicated, and how it works remains unclear. But may be beneficial.

Probiotics

Foods such as kefir and yogurt can boost the levels of bacteria.

Healthy gut microbiota may reduce the signs and risk of depression, based on some 2016 meta-analysis. The researchers indicated that Lactobacillus and Bifidobacterium might help.

Weight control

This increased danger could possibly be due to the hormonal and immunological changes which happen in people with obesity.

Someone who is overweight or has obesity may desire to seek advice from with a dietitian or their health care provider about ways to manage their own weight.

The Dietary Approaches to Stop Hypertension (DASH) diet, which health authorities recommend, can help reduce blood pressure and improve overall health.

Theres also evidence it may help with weight loss and may reduce the risk of melancholy.

Foods to avoid

The symptoms of depression can aggravate.

Convenience foods, such as fast food and junk foods, can be full of calories and low in nutrients.

Research Have suggested that those who consume a lot of food are more likely to have depression than those who eat mainly fresh produce.

Processed foods, particularly those high in sugars and refined carbs, May contribute to a greater risk of depression. When a person eats carbs that are refined, the bodys energy levels grow rapidly but crash. A rapid low can follow, although an immediate increase may be given by A bar of chocolate.

Its ideal to opt.

Processed oils

Processed and polyunsaturated fats can activate inflammation, and they might also impair brain function and aggravate the symptoms of depression.

Fats to avoid include:

Trans fats, that are present in many processed foodsfats in red and processed meatssafflower and corn oil, which can be saturated in omega-6 fatty acids

At least one study has found that a moderate consumption of caffeinein the form of java , may assist people with depression. The benefits of caffeine could be due to properties that are antioxidants and its stimulant effect.

Coffeeteachocolatesodasenergy beverages

There is some evidence That small amounts of caffeine can reduce improve and stress mood. Some research has found that it might increase feelings of stress, stress, and depression in kids of high school age.

While caffeine may benefit some individuals, Its Best to:

Consume it in moderationavoid products with a high caffeine content, such as energy drinksavoid caffeine after midday

Go here to read the rest:
What Foods Are Good For Helping Depression? - The Health Eaducation

Recommendation and review posted by Bethany Smith

Last week, the cystic fibrosis community celebrated the approval of a new drug from Vertex (VRTX) Pharmaceuticals, a decision that offers the large majority of patients access to cutting-edge treatments.

Those treatments, however, dont cover patients with certain rare mutations. And they are not cures for anyone.

Seeking to address those issues, the Cystic Fibrosis Foundation on Wednesday unveiled a $500 million initiative aimed at developing treatments for patients who arent helped by the Vertex drugs and, ultimately, at finding cures for all CF patients. The message is: Despite the success, there is still work to be done.

advertisement

Its not the entire story, Dr. Michael Boyle of the Cystic Fibrosis Foundation said about the Vertex therapies. The rest of the story is: How are we going to make sure there are treatments for the underlying cause of CF for 100% of patients?

The new Path to a Cure plan, which was announced ahead of the foundations North American Cystic Fibrosis Conference taking place later this week in Nashville, will fund some basic research. But Boyle, the foundations senior vice president of therapeutics development, said the majority of the money will go to support clinical programs.

The $500 million will be doled out through 2025, said Boyle, who is taking over as CEO of the foundation come January.

Cystic fibrosis is a progressive disease that damages the lungs, along with other organs, and can ultimately lead to respiratory failure. It occurs when mutations in the CFTR gene form a dysfunctional version of a protein, also called CFTR, setting off a cascade that ends with mucus clogging the lungs and frequent infections.

Vertexs drugs, the first of which was approved in 2012, have changed the landscape for patients with more common CF-causing mutations. (There are more than 1,700 mutations in the CFTR gene that cause the disease.) The latest medication, Trikafta, is a combination of three therapies that extends the reach of the drugs to an estimated 90% of patients.

All of thedrugs, called modulators, work by tweaking the location and shape of the CFTR protein to get it to function properly.

The bulk of the patients who do not respond to the modulators have CF caused by nonsense mutations (also called stop or X mutations), which fail to generate a version of CFTR close enough to the healthy form for modulators to coax activity from.

Given the urgency of the situation and the fact that unfortunately the research and drug development for nonsense mutations lags so far behind, we need to be throwing our efforts into a ton of different approaches and pursuing all of them with the same intensity and vigor, said Emily Kramer-Golinkoff, who has nonsense mutation-caused CF and, with her family, started Emilys Entourage to help develop treatments for patients with nonsense mutations.

The modulators also do not work on some rare CF mutations; in others they have not been tested.

Hispanic CF patients more frequently have these uncommon mutations and, as a result, many have been left without modern therapies, said Dr. Meghan McGarry, a pediatric pulmonologist at the University of California, San Francisco. She estimated that two-thirds of Hispanic patients have mutations targeted by the Vertex drugs, compared to 90% of patients generally.

For the patients where [modulators] work, its amazing, said McGarry, who has received funding from the Cystic Fibrosis Foundation before. But theres a whole group where they dont work.

The CF Foundations plan outlines a number of clinical approaches that it intends to support. Some, including an approach called a readthrough therapy, would be specific to nonsense mutations. But others, including those involving RNA and DNA, would be mutation agnostic, meaning they would work for all CF patients.

While modulators have been transformative for some patients, they are not cures. Gene therapies (delivering a healthy CFTR gene with the help of a harmless virus) or gene editing with tools like CRISPR have potential as one-time therapies that can permanently overcome the underlying mutation, so patients would no longer need to take modulators or other drugs.

Some of the foundations funding will also go toward researching how to deliver therapies. Lung cells are difficult targets for two reasons, Boyle said: First, they are more primed than others to attack anything that appears foreign which could extend to genetic therapies making their way into the cells. And second, lung cells turn over frequently, so the treatments would need to reach the cells that make lung cells to deliver a lasting benefit.

The lungs are more challenging than tissues like bone marrow or the liver, Boyle said.

Read this article:
Cystic Fibrosis Foundation rolls out $500 million cures initiative - STAT

Recommendation and review posted by Bethany Smith

The National Institutes of Health (NIH) and the Bill & Melinda Gates Foundation will each invest $100 million over the next four years to speed the development of affordable gene therapies for sickle cell disease (SCD) and the human immunodeficiency virus (HIV) on a global scale.

This unprecedented collaboration focuses from the get-go on access, scalability and affordability of advanced gene-based strategies for sickle cell disease and HIV to make sure everybody, everywhere has the opportunity to be cured, not just those in high-income countries, said NIH Director Francis S. Collins, MD, PhD.

Seventy-five percent of babies born with SCD live in sub-Saharan Africa. It is hoped that experimental gene therapies would advance to clinical trials in the United States and relevant African countries within the next seven to 10 years, and that safe, effective, and inexpensive gene therapies be made available globally, including in low-resource settings where the cost and complexity of these therapies make them inaccessible to many.

In recent years, gene-based treatments have been groundbreaking for rare genetic disorders and infectious diseases, Trevor Mundel, MD, PhD, president of the global health program at the Bill & Melinda Gates Foundation said in a news release.

While these treatments are exciting, people in low- and middle-income countries do not have access to these breakthroughs. By working with the NIH and scientists across Africa, we aim to ensure these approaches will improve the lives of those most in need and bring the incredible promise of gene-based treatments to the world of public health, he added.

Hemoglobin is the protein in red blood cells that binds oxygen, allowing oxygen to be transported around the body. Mutations in the HBBgene, which encodes a component of hemoglobin, result in the formation of sickle hemoglobin that causes sickle cell anemia.

Currently, gene therapies for SCD involves altering the patients own hematopoietic stem cells (bone marrow cells that divide and specialize to produce blood cells including red blood cells). Genes are introduced into the cells using a modified, harmless virus (known as a viral vector). The cells are then transplanted back into the patient where they will produce healthy red blood cells. Gene therapy has an advantage over a bone marrow transplant, as it circumvents the complications associated with a bone marrow donation.

The first goal of the collaboration between the NIH and the Gates Foundation is to develop an easy-to-administer gene-based intervention to correct the mutations in the HBBgene or deliver a functional gene that will promote the production of normal levels of hemoglobin without the need to extract cells from patients and modify them in the lab before introducing the cells back. However, this strategy, known as in vivotreatment, requires the advancement of more efficient delivery systems that can deliver the gene therapy specifically to hematopoietic stem cells.

A second goal of the collaboration will be to work together with African partners and bring potential therapies to clinical trials.

Further research is required to understand the burden of SCD in sub-Saharan Africa and to screen newborns at high risk for the disease, a task that the National Heart, Lung and Blood Institute (NHLBI) has started to tackle by building the necessary infrastructure for clinical research.

The NIH and the Gates Foundation will help boost this infrastructure to allow point-of-care screening (for example, when infants receive vaccinations), and to initiate a standard of care. This will occur outside of the official collaboration.

Our excitement around this partnership rests not only in its ability to leverage the expertise in two organizations to reduce childhood mortality rates in low-resource countries, but to bring curative therapies for sickle cell disease and HIV to communities that have been severely burdened by these diseases for generations, said Gary H. Gibbons, MD, director of the NHLBI.

A persons health should not be limited by their geographic location, whether rural America or sub-Saharan Africa; harnessing the power of science is needed to transcend borders to improve health for all, he added.

Matshidiso Rebecca Moeti, the regional director for Africa at the World Health Organization said, We are losing too much of Africas future to sickle cell disease and HIV.

Beating these diseases will take new thinking and long-term commitment. Im very pleased to see the innovative collaboration announced today, which has a chance to help tackle two of Africas greatest public health challenges, Moeti added.

Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.

Total Posts: 94

Margarida graduated with a BS in Health Sciences from the University of Lisbon and a MSc in Biotechnology from Instituto Superior Tcnico (IST-UL). She worked as a molecular biologist research associate at a Cambridge UK-based biotech company that discovers and develops therapeutic, fully human monoclonal antibodies.

View post:
SCD, HIV Gene Therapy Efforts Get $200M from NIH, Gates Foundation - Sickle Cell Anemia News

Recommendation and review posted by Bethany Smith

Researchers identified a mutated gene in three rhesus monkeys that is associated with Bardet-Biedl Syndrome (BBS), a rare genetic disease that causes childhood-onset blindness. The science team indicates it is the first naturally occurring case of a nonhuman primate model of the syndrome and could lead to potential treatments.

The disease also leads to kidney problems, polydactylyextra fingers or toesobesity, hypogonadism, and other symptoms. It occurs in about one in 140,000 to 160,000 births in North America.

There is no cure for Bardet-Biedel Syndrome today, but having a naturally occurring animal model for the condition could help us find one in the future, Martha Neuringer, professor of neuroscience at the Oregon National Primate Research Center at Oregon Health & Science University, told MedicalXpress.

The findings have broader implications than just BBS. BBS is part of a family of diseases called retinitis pigmentosa, a disease of the retina. This larger family of eye diseases affects about one in 3,500 to 4,000 people in the U.S. and Europe.

The research was published in the journal Experimental Eye Research.

The authors note, The development of therapies for retinal disorders is hampered by a lack of appropriate animal models. Higher nonhuman primates are the only animals with retinal structure similar to humans, including the presence of a macula and fovea. However, few nonhuman primate models of genetic retinal disease are known.

One of the first gene therapies approved for use is Spark Therapeutics Luxturna (voretigene neparvovec) for a rare, genetic form of blindness called retinal dystrophy. The eye is a good target for gene therapies because the therapies can be directly injected into the organ, rather than requiring a systemic approach.

The development of Luxturna was built on the discovery of a gene mutation in dogs in the 1990s linked to Lebers congenital amaurosis, which causes blindness.

Neuringers research team hopes their discovery can lead to a similar therapy for BBS.

Neuringer and her research group identified two monkeys that were related and did not have cells key to vision. Colleagues Betsy Ferguson and Samuel Petersen than analyzed the monkeys genomes and found both had a mutation of the BBS7 gene, which is one of at least 14 genes associated with BBS.

Fergusons research has involved sequencing the genomes of 2,000 rhesus macaques at the nonhuman primate research center. She was then able to identify a third monkey with the same mutation. That monkey had serious vision loss when it was identified in 2018. At the time, the monkey was three-and-a-half years old, but it had adapted to its social group to such an extent that the blindness wasnt obvious.

Neuringer and her group are using a National Eye Institute grant to breed more monkeys with the naturally occurring BBS7 mutations, which will provide researchers with more laboratory animals to work with to develop treatments for these diseases.

The BBS genes encode proteins for the function of cilia. Models of BBS have been developed from rodents, fish and roundworms, but they are not as closely related to human eyes as primate models.

One of the common symptoms of BBS in humans is obesity. However, in the monkeys, only one had a body weight considered higher than average. This could be related to other factors, including the development of kidney disease. One of the monkeys also has relatively smaller testicles, but with only three monkeys, its not clear if the mutation is behind these characteristics.

See the rest here:
Oregon Researchers ID Monkey Mutations Associated with Rare Blindness in Humans - BioSpace

Recommendation and review posted by Bethany Smith

CAMBRIDGE, Mass.--(BUSINESS WIRE)--

Dr. Carl Christel Heads U.S. Office and Hires Rajesh Panigrahi and Roman Braun

SIRION Biotech International Inc., a wholly-owned subsidiary of SIRION Biotech GmbH in Germany (SIRION), offering the most comprehensive portfolio of custom viral vectors for preclinical studies, today announced that Dr. Carl Christel, PhD, Vice President, U.S. Operations, has relocated to the U.S. to head SIRIONs Cambridge office. Dr. Christel has lived and worked as a molecular biologist on both sides of the Atlantic. After receiving his PhD at the Technical University Munich (Germany), he completed four productive years as postdoctoral fellow at the University of Iowa Carver College of Medicine. With his well-based understanding of molecular physiology and bilingual background, Carl will be a vital connection between SIRIONs German-based headquarters and the U.S. market, ensuring streamlined global communications. In addition, SIRION has hired Rajesh Panigrahi, PhD, and Roman O. Braun, PhD, to further support SIRIONs U.S. clients.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191031005261/en/

Dr. Panigrahi is an experienced virologist who has devoted over ten years of research to investigating the connection between viruses and certain forms of cancer. As a postdoctoral fellow at UMass Medical School in Worcester, Massachusetts, his research was mainly focused on developing the therapeutic EBV vaccine as well as identifying the best AAV vector for the treatment of EBV lymphomas. With his experience in virology, he joined Sanofi as a scientist, where he was involved in the drug development process. His academic training and research encompass virology, molecular biology, microbiology, biochemistry, and genetics.

Dr. Braun is a scientific leader with broad experience in quantitative research, autoimmunity, cancer, pathogen-host interaction, and vaccine development. He studied in Konstanz, Germany and Bern, Switzerland and graduated with a PhD in Immunology. His experience includes being a postdoctoral fellow in immunology and vaccine development at the Institute for Virology & Immunology in Bern, Switzerland where he developed novel vaccine formulations and systems biological approaches to understand vaccine response in livestock. From there Dr. Braun moved to Harvard Medical School and Childrens Hospital in Boston, Massachusetts and was involved in research to understand inflammatory diseases, cancer, and hematological disorders.

We are laser-focused on delivering the worlds most comprehensive viral vector technology platforms to expedite gene therapy research and advance drug development in the U.S. market, said Dieter Lingelbach, Chief Operating Officer of SIRION Biotech. With Carl leading our Cambridge office, well be especially well positioned to broaden our reach into the U.S. market, and we welcome Rajesh and Roman to the team and look forward to utilizing their expertise to support our existing customers and further drive our international growth.

About SIRION Biotech International Inc.

SIRION Biotech International is a wholly-owned subsidiary of SIRION Biotech GmbH providing custom engineering and manufacturing services of viral vectors for the life sciences industry. SIRION offers one of the worlds most comprehensive viral vector technology platforms based on lenti-, adeno-, and adeno-associated viruses which expedites gene therapy research and advances drug development. Its unique focus on improving transduction efficiencies and safety make SIRION Biotech a valuable technology partner for gene and cell therapy trials. LentiBOOSTTM transduction reagent is actively used to improve, among others, hematopoietic cell transductions in clinical trials. NextGen AAV capsid evolution projects aim to improve tissue targeting and immune escape of capsids to usher in a new generation of therapeutics for international gene therapy companies. http://www.sirion-biotech.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20191031005261/en/

Read more:
SIRION Biotech Continues to Expand into the U.S. Viral Vector Market - Yahoo Finance

Recommendation and review posted by Bethany Smith

CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) today reported financial results and business highlights for the third quarter ended September 30, 2019.

During the third quarter we advanced our country-by-country launch plans in Europe and, with the recent approval of the commercial drug product manufacturing specifications for ZYNTEGLO, we moved one step closer to our goal of treating patients suffering from TDT in early 2020, said Nick Leschly, chief bluebird. Also this quarter, we presented updated data from the Phase 2/3 Starbeam study in patients with CALD. To report that patients continued to be free of MFDs at up to five years of follow-up is something were tremendously proud to do for these families, and we look forward to advancing that program in the regulatory process next year. Looking ahead, we plan to provide clinical updates for ZYNTEGLO and across the rest of our portfolio, including LentiGlobin in sickle cell disease, bb21217 in multiple myeloma, and from our registration-enabling KarMMa study of ide-cel in patients with multiple myeloma by the end of this year. Id like to thank all the bluebirds around the globe for their tireless focus on doing the right thing for our patients weve seen amazing progress thus far in 2019 and I look forward to ending the year on a strong note.

Recent Highlights:

TDT

CALD

COMPANY

Upcoming Anticipated Milestones:

Third Quarter 2019 Financial Results

About bluebird bio, Inc.bluebird bio is pioneering gene therapy with purpose. From our Cambridge, Mass., headquarters, were developing gene therapies for severe genetic diseases and cancer, with the goal that people facing potentially fatal conditions with limited treatment options can live their lives fully. Beyond our labs, were working to positively disrupt the healthcare system to create access, transparency and education so that gene therapy can become available to all those who can benefit.

bluebird bio is a human company powered by human stories. Were putting our care and expertise to work across a spectrum of disorders by researching cerebral adrenoleukodystrophy, sickle cell disease, transfusion-dependent -thalassemia and multiple myeloma using three gene therapy technologies: gene addition, cell therapy and (megaTAL-enabled) gene editing.

bluebird bio has additional nests in Seattle, Wash.; Durham, N.C.; and Zug, Switzerland. For more information, visit bluebirdbio.com.

Follow bluebird bio on social media: @bluebirdbio, LinkedIn, Instagram and YouTube.

ZYNTEGLO, LentiGlobin and Lenti-D are trademarks of bluebird bio, Inc.

The full common name for ZYNTEGLO: A genetically modified autologous CD34+ cell enriched population that contains hematopoietic stem cells transduced with lentiviral vector encoding the A-T87Q-globin gene.

Forward-Looking StatementsThis release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the companys financial condition, results of operations, as well as statements regarding the plans for regulatory submissions and commercialization for ZYNTEGLO and the companys product candidates, including anticipated regulatory milestones, planned commercial launches, planned clinical studies, as well as the companys intentions regarding the timing for providing further updates on the development and commercialization of ZYNTEGLO and the companys product candidates. Any forward-looking statements are based on managements current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risks that the preliminary positive efficacy and safety results from our prior and ongoing clinical trials will not continue or be repeated in our ongoing or future clinical trials, the risk of cessation or delay of any of the ongoing or planned clinical studies and/or our development of our product candidates, risks that the current or planned clinical trials of our product candidates will be insufficient to support regulatory submissions or marketing approval in the United States and European Union, the risk that we will encounter challenges in the commercial launch of ZYNTEGLO in the European Union, including in managing our complex supply chain for the delivery of drug product or in the adoption of value-based payment models or in obtaining sufficient coverage or reimbursement for our products if approved, the risk that our collaborations, including the collaboration with Celgene, will not continue or will not be successful, and the risk that any one or more of our product candidates, will not be successfully developed, approved or commercialized. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled Risk Factors in our most recent Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and bluebird bio undertakes no duty to update this information unless required by law.

bluebird bio, Inc.Consolidated Statements of Operations(in thousands, except per share data)(unaudited)

For the three months ended September 30,

For the nine months ended September 30,

2019

2018

2019

2018

Revenue:

Collaboration revenue

$

6,575

$

10,926

$

29,310

$

33,971

License and royalty revenue

2,335

602

5,367

1,365

Total revenues

8,910

11,528

34,677

35,336

Operating expenses:

Go here to see the original:
bluebird bio Reports Third Quarter 2019 Financial Results and Highlights Operational Progress - Business Wire

Recommendation and review posted by Bethany Smith

Seven months ago, Thermo Fisher spent $1.7 billion to add a gene therapy company to its sprawling biotech business, purchasing Brammer Bio. Now theyve signed a collaboration deal with another, newly well-funded, company from the same founder to expand its gene therapy work into the microbiome.

Thermo Fisher announced a collaboration with microbiome product manufacturer Arranta Bio as the startup announced an $82 million funding round. The young CDMO will provide its live biopharmaceuticals to Thermo Fisher to use in gene therapy production.

Thermo Fisher has entered the gene therapy space as the field fills with biotechs who,eyeing the clinic, will demand more of the necessary materials than existing manufacturers have the capacity to provide. An October investor report from Jefferies argued that going forward, theability to manufacture gene therapy products may be just as important as perfecting the science behind them, Biopharma Dive reported.

A vast majority of companies rely on contract manufacturing organizations to fill this role, they wrote. However, with the recent explosion of gene therapy programs, a shortage of CMOs and human capital has resulted, driving many companies to bring manufacturing in-house.

Arrantas CEO and founder Mark Bamforth has a long relationship with Thermo Fisher, selling them Brammer this year and in 2014 selling Gallus Biopharmaceuticals to Patheon, now a Thermo Fisher subsidiary. The sole institutional investor for this funding round was Ampersand Capital Partners where Bamforth is also a partner. The rest came from company founders and colleagues, along with an infusion from Thermo Fisher.

Originally posted here:
Thermo Fisher hooks gut onto its gene therapy pipeline, inks new collaboration pact - Endpoints News

Recommendation and review posted by Bethany Smith

Amgen exiting neuroscience R&D

Amgen Inc. (AMGN) announced during the 3Q-2019 earnings call conference on 10/29/2019, its exit from the neurosciences research and early development programs. The company's head of research and development, David Reese stated:

Upon careful evaluation of our pipeline and the challenges inherent in developing drugs for major neurologic diseases, we've made the decision to end our neuroscience research and early development programs with the exception of programs centered on neuro inflammation that will be pursued by our inflammation TA."

The company saw success with aimovig for migraine patients, but its study of a late-stage candidate in Alzheimer's disease in partnership with Novartis (NVS) was halted a few months back. In response to a caller's question about the neuroscience decision, David said that the company was looking at alternative models to maintain a hand in the neuroscience segment. It could potentially be with venture capital or maybe academic institutions. The company's CEO, Bob Bradway added that Amgen would capitalize on the insights from its work with deCODE in human genome sequencing. Amgen's R&D cost-cutting could be an indirect effect of its product price restructuring strategy following the results of such exercise with repatha, and aimovig, which are now available at "relatively affordable co-pay levels." According to unconfirmed reports, there will be 180 layoffs across the company, with the highest impact being at Cambridge, MA location.

In a major setback to Novartis, the U.S. FDA has suspended enrollment of new study participants in the company's phase 1 STRONG trial of zolgensma (anasemnogene abeparvovec-xioi) (AVX-101) in patients with Type 2 spinal muscular atrophy (SMA). The company has clarified that this was a partial clinical hold on the intrathecal (injection into the spinal canal) administration of the gene therapy. The hold was the result of the FDA receiving information from Novartis' subsidiary AveXis, about a preclinical animal study that showed "dorsal root ganglia (DRG) mononuclear cell inflammation, sometimes accompanied by neuronal cell body degeneration or loss." AveXis is already under investigation for data manipulation related to the company's submission for approval of zolgensma. Novartis blamed two "senior," "founder" executives at AveXis for the scandal, who have since been terminated.

Novartis further clarified that the partial clinical hold does not affect the approved use of zolgensma and IV administration.

Zolgensma competitors: risdiplam from the collaboration of Roche (OTCQX:RHHBY) and PTC Therapeutics, Inc. (PTCT), and spinraza from the collaboration of Biogen (BIIB) and Ionis Pharmaceuticals, Inc. (IONS) stand to benefit. All the four companies' stocks gained, while Regenxbio Inc. (RGNX) shares lost over 10% as the company receives milestones and royalties from zolgensma licensor AveXis.

This company's stock price touched the 52 weeks low and high: $0.9 and $3.6 respectively, in the past one week (10/25/2019 to 10/30/2019), and a gain of over 57% year-to-date. IVERIC bio, Inc. (ISEE) is a clinical-stage company developing treatments for patients with orphan, inherited retinal diseases with significant unmet medical needs. Iveric announced on 10/28/2019, initial top-line data from the randomized, controlled, phase 2b clinical trial of Zimura (avacincaptad pegol) in patients with geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). The pre-specified primary endpoint of reduction in the mean rate of GA growth over 12 months was met. Data showed statistical significance, with the reduction in the mean rate of GA growth being 27.38% (p-value = 0.0072) for the zimura 2 mg group, and 27.81% (p-value = 0.0051) for the zimura 4 mg group, as compared to the respective corresponding sham control groups. Zimura was generally well tolerated, with no zimura treatment-related inflammation or discontinuations from the trial. There also were no ocular serious adverse events (SAEs) or cases of endophthalmitis reported in the study eye. The most frequently reported ocular adverse events (AEs) were related to the injection procedure.

Zimura is a complement factor C5 inhibitor. It binds to C5, inhibiting its cleavage into terminal C5a and C5b, thereby decreasing the activation of inflammasomes and the formation of membrane attack complex (MAC). The potential of this mechanism to prevent or reduce the degeneration of retinal pigment epithelial (RPE) cells provides the basis for the zimura monotherapy in GA secondary to dry AMD, and in stargardt disease (STGD1). The company's therapeutics pipeline includes a HtrA1 inhibitor candidate in preclinical stage for GA secondary to dry AMD.

The company also has a gene therapy focused pipeline of product candidates in the preclinical stage.

(Pipeline images source: company website)

The company seems to be looking for partnerships in zimura monotherapy for both GA secondary to dry AMD and STGD1.

AbbVie (ABBV) announced positive top-line data from the SELECT-PsA 2 phase 3 study of RINVOQ (upadacitinib) in adult patients with active psoriatic arthritis who have responded inadequately to one or more biologic disease-modifying anti-rheumatic drugs (bDMARDs). The study results showed that both doses of RINVOQ: 15 mg and 30 mg, once daily, met the primary endpoint at week 12 versus placebo, with 57% on the 15 mg arm and 64% on the 30 mg arm of RINVOQ compared to 24% in the placebo arm achieving ACR20. At week 12, patients on RINVOQ treatment arms also had greater improvements in physical function, as measured by the Health Assessment Questionnaire Disability Index (HAQ-DI). At week 16, 52% of patients on 15 mg and 57% of patients on 30 mg of RINVOQ achieved a Psoriasis Area Severity Index (PASI) 75 response compared to 16% on placebo. At week 24, 25% of patients on 15 mg and 29% of patients on 30 mg RINVOQ achieved minimal disease activity (MDA) compared to 3% of the placebo group.

SELECT-PsA 2 Efficacy Results

RINVOQ 15 mg

(n=211)

RINVOQ 30 mg

(n=218)

Placebo

(n=212)

p-value

ACR20a at week 12

57%

64%

24%

p<0.0001

ACR50a at week 12

32%

38%

5%

p<0.0001

ACR70a at week 12

9%

17%

0.5%

p<0.0001

HAQ-DIb at week 12

-0.30

-0.41

-0.10

PASI 75c at week 16

52%

57%

16%

p<0.0001

MDAd at week 24

25%

29%

3%

p<0.0001

(Table source: company PR linked above)

There were no new safety signals, putting the safety profile of RINVOQ consistent with that of previous studies across indications. Discovered and developed by AbbVie, RINVOQ is a selective and reversible JAK inhibitor being studied as a once-daily therapy in psoriatic arthritis and multiple immune-mediated diseases. Psoriatic arthritis is a heterogeneous systemic inflammatory disease affecting more than 50 million people worldwide.

Thanks for reading. At the Total Pharma Tracker, we do more than follow biotech news. Using our IOMachine, our team of analysts work to be ahead of the curve.

That means that when the catalyst comes that will make or break a stock, we've positioned ourselves for success. And we share that positioning and all the analysis behind it with our members.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Link:
Amgen Exits Neuroscience Research: The Good, Bad, And Ugly Of Biopharma - Seeking Alpha

Recommendation and review posted by Bethany Smith

The BLOOD CANCER DRUGS market research report added by Report Ocean, is an in-depth analysis of the latest trends, market size, status, upcoming technologies, industry drivers, challenges, regulatory policies, with key company profiles and strategies of players. The research study provides market introduction, BLOOD CANCER DRUGS market definition, regional market scope, sales and revenue by region, manufacturing cost analysis, Industrial Chain, market effect factors analysis, BLOOD CANCER DRUGS market size forecast, 100+ market data, Tables, Pie Chart, Graphs and Figures, and many more for business intelligence.

The global blood cancer drugs market is anticipated to reach USD 55.6 billion by 2025.

UPTO 30% OFF ON SINGLE USER PDF: https://www.reportocean.com/industry-verticals/sample-request.php?report_id=5256

In the BLOOD CANCER DRUGS Market, some of the major companies are:

Johnson & Johnson Inc., Amgen Inc., Bayer AG., Pfizer, Inc., AbbVie Inc., Roche Holding AG., Celgene Corporation, AstraZeneca, Novartis AG, GlaxoSmithKline PLC, Merck & Co., Inc., and Eli Lily & Co. among others.

The report consists of various chapters and company profiling is a major among them. Company profiling garners business intelligence and track key elements of a business, such as:

BLOOD CANCER DRUGS Market: Insights

The global blood cancer drugs market is anticipated to reach USD 55.6 billion by 2025. The demand for blood cancer drug is primarily driven by growing death incidences by blood cancer, and continuous innovation for developing novel treatments with the help of several ongoing clinical trials. Moreover, increasing research and development of biological and targeted therapies as treatment will spur the blood cancer drugs market during the upcoming period. However, the high price of drugs and the stringent government policies will limit the growth of blood cancer drugs market during the forecast period.

Most of the blood cancers start in the bone marrow, where blood is produced. In blood cancer the growth of normal blood cells is dislodged by the uncontrollable growth of abnormal blood cells. These cancerous cells prevent the blood from performing many of its functions. Hence, the existing treatments of blood cancer are being the foundation for developing the new drugs. The steady flow of the blood cancer drugs has created opportunity for research and development in the existing market. For instance, Amgen Inc. received approval for BLINCYTO in July 2017, which is used in treating B-cell precursor Acute Lymphoblastic leukemia. Similarly, European blood cancer drugs market witnessed the approvals of Gazyvaro, by Roche AG that is used in treating advanced follicular lymphoma. Also, novel technologies like CAR-T are likely to be launched this year.

The global blood cancer drugs market is segmented into blood cancer type, drugs and treatment approaches. On the basis of blood cancer type, the global blood cancer drugs market is segmented into leukemia, lymphoma and myeloma. The lymphoma segment is expected to drive the majority market of blood cancer drugs followed by leukemia. The global market of this segment is primarily driven by the increasing prevalence of lymphoma, and presence of effective treatments in the market. On the basis of drugs, the global blood cancer drugs market is further categorized into Rituaxan/Mabthera (Rituximab), Gleevac/Glivec (Imatinib), Revlimid (Lenalidomide), Velcade (Bortezomib), Tasigna (Nilotinib), Pomalyst (Pomalidomide), Vidaza (Azacitidine), Kyprolis (Carfilzomib), Adcetris (Brentuximab Vedotin), and Others. This continuous innovation for treating various sub-types of blood cancers has led to the development of novel types of treatments. For instance, the combination of Revlimid and Velcade has emerged as the preferential drugs in trials for treating multiple myeloma.

On the basis of treatment approaches the global blood cancer drugs market is further segmented into Chemotherapeutic, mAbs/Targeted Therapies, and Immunotherapeutic. Due to availability of variety of chemotherapeutic agent in the market chemotherapeutic drugs are expected to hold the higher share in blood cancer drugs market. Moreover, their effectiveness for the treatment of blood cancer and increasing number of cancer patients globally has garnered more demand for chemotherapeutic drugs throughout the world.

Geographically, the global blood cancer drugs market is segmented into North America, Europe, Asia Pacific, and the rest of the world. North America dominates the blood cancer drugs market which is followed by Europe and Asia Pacific. Favorable reimbursement policies, surge in R&D investments of various companies, as well as the increase in the number of blood cancer treatments are some of the major factors responsible for the growth of North Americas blood cancer drugs market. Moreover, Asia-Pacific region has been identified as the lucrative market for the for blood cancer drugs due to increasing awareness of the use of these drugs, increased healthcare expenditure, and rising per capita disposable income. These are some of the major factors which are influencing the growth of the blood cancer drugs in Asia-pacific region.

The leading companies operating in this industry include Johnson & Johnson Inc., Amgen Inc., Bayer AG., Pfizer, Inc., AbbVie Inc., Roche Holding AG., Celgene Corporation, AstraZeneca, Novartis AG, GlaxoSmithKline PLC, Merck & Co., Inc., and Eli Lily & Co. among others.

Key Findings from the study suggest blood cancer drugs in the market are much innovative and manufacturers are progressively concentrating on innovation of combination drugs. Companies are in a stage of development of new drugs in order to provide novel treatments for blood cancer. The immunotherapy segment is anticipated to grow at a high growth rate over the forecast period. The growth of this segment is primarily driven by increased awareness for its use as an alternative and effective treatment for blood cancer. North America is presumed to dominate the global blood cancer drugs market over the forecast period. Asia Pacific region which shows signs of high growth potential owing to the booming economies of India, and China.

Get a Sample Report for more Expert and Official insights: @https://www.reportocean.com/industry-verticals/sample-request.php?report_id=5256

The Global BLOOD CANCER DRUGS Market is segmented into various sub-groups to understand the market scenario in detail, the market segmentation are as follows:

[By Blood Cancer Type (Leukemia (Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia), Lymphoma (Hodgkin Lymphoma, Non-Hodgkin Lymphoma (B-Cell Lymphoma, T-Cell Lymphoma)), and Myeloma; By Drugs (Rituaxan/Mabthera (Rituximab), Gleevac/Glivec (Imatinib), Revlimid (Lenalidomide), Velcade (Bortezomib), Tasigna (Nilotinib), Pomalyst (Pomalidomide), Vidaza (Azacitidine), Kyprolis (Carfilzomib), Adcetris (Brentuximab Vedotin), and Others); By Treatment Approaches (Chemotherapeutic, mAbs/Targeted Therapies, and Immunotherapeutic); By Region]

Furthermore, the years considered for the study are as follows:

Historical year 2013-2017

Base year 2018

Forecast period** 2019 to 2025 [** unless otherwise stated]

Regional split of the Global BLOOD CANCER DRUGS Market research report is as follows:

The market research study offers in-depth regional analysis along with the current market scenarios. The major regions analyzed in the study are:

Key highlights and important features of the Report:

Overview and highlights of product and application segments of the global BLOOD CANCER DRUGS Market are provided. Highlights of the segmentation study include price, revenue, sales, sales growth rate, and market share by product.

Explore about Sales data of key players of the global BLOOD CANCER DRUGS Market as well as some useful information on their business. It talks about the gross margin, price, revenue, products, and their specifications, type, applications, competitors, manufacturing base, and the main business of key players operating in the BLOOD CANCER DRUGS Market.

Explore about gross margin, sales, revenue, production, market share, CAGR, and market size by region.

Describe BLOOD CANCER DRUGS Market Findings and Conclusion, Appendix, methodology and data source;

Research Methodology:

The market research was done by adopting various tools under the category of primary and secondary research. For primary research, experts and major sources of information have been interviewed from suppliers side and industries, to obtain and verify the data related to the study of the Global BLOOD CANCER DRUGS Market. In secondary research methodology, various secondary sources were referred to collect and identify extensive piece of information, such as paid databases, directories and annual reports and databases for commercial study of the Global BLOOD CANCER DRUGS Market. Moreover, other secondary sources include studying technical papers, news releases, government websites, product literatures, white papers, and other literatures to research the market in detail.

Browse Premium Research Report with Tables and Figures at @ https://www.reportocean.com/industry-verticals/details?report_id=5256

There are 15 Chapters to display the Global BLOOD CANCER DRUGS Market:

Chapter 1, to describe Definition, Specifications and Classification of Global BLOOD CANCER DRUGS, Applications of, Market Segment by Regions;Chapter 2, to analyze the Manufacturing Cost Structure, Raw Material and Suppliers, Manufacturing Process, Industry Chain Structure;Chapter 3, to display the Technical Data and Manufacturing Plants Analysis of , Capacity and Commercial Production Date, Manufacturing Plants Distribution, Export & Import, R&D Status and Technology Source, Raw Materials Sources Analysis;Chapter 4, to show the Overall Market Analysis, Capacity Analysis (Company Segment), Sales Analysis (Company Segment), Sales Price Analysis (Company Segment);Chapter 5 and 6, to show the Regional Market Analysis that includes United States, EU, Japan, China, India & Southeast Asia, Segment Market Analysis (by Type);Chapter 7 and 8, to explore the Market Analysis by Application Major Manufacturers Analysis;Chapter 9, Market Trend Analysis, Regional Market Trend, Market Trend by Product Type, Market Trend by Application;Chapter 10, Regional Marketing Type Analysis, International Trade Type Analysis, Supply Chain Analysis;Chapter 11, to analyze the Consumers Analysis of Global BLOOD CANCER DRUGS by region, type and application;Chapter 12, to describe BLOOD CANCER DRUGS Research Findings and Conclusion, Appendix, methodology and data source;Chapter 13, 14 and 15, to describe BLOOD CANCER DRUGS sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source.

About Report Ocean:

We are the best market research reports provider in the industry. Report Ocean believe in providing the quality reports to clients to meet the top line and bottom line goals which will boost your market share in todays competitive environment. Report Ocean is one-stop solution for individuals, organizations, and industries that are looking for innovative market research reports.

Get in Touch with Us:

Name: Varda

Email: [emailprotected]

Address: Classic Tower, Rajnagar Extension, Ghaziabad, 201017 India

Tel: +1 888 212 3539 (US TOLL FREE)

Website: https://www.reportocean.com/

More:
Cancer Gene Therapy Market Research, Insights, Revenue and Forecast by 2023 - Health News Office

Recommendation and review posted by Bethany Smith

CAMBRIDGE, Mass., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), reported operational highlights and financial results for the third quarter ended September 30, 2019.

In 2019, we continued to leverage the breadth of our genome editing platform to advance our in vivo and engineered cell therapy programs. We have demonstrated that we can knock out a disease-causing gene as well as introduce a functional gene to restore normal protein production. Now, we have achieved consecutive editing in vivo by combining both these edit types, further highlighting the versatility of our modular platform, said Intellia President and Chief Executive Officer, John Leonard, M.D. Our full-spectrum strategy and platform capabilities are enabling Intellias development of a robust pipeline to address a range of severe diseases. We look forward to the planned nomination of our first engineered cell therapy development candidate for acute myeloid leukemia by year-end and the submission of our first IND application for NTLA-2001 for the treatment of transthyretin amyloidosis in mid-2020.

Third Quarter 2019 and More Recent Operational Highlights

Upcoming Milestones

The Company has set forth the following for pipeline progression:

Upcoming Events

The Company will participate in the following investor events:

Third Quarter 2019 Financial Results

Financial Guidance

Intellia expects that its cash, cash equivalents and marketable securities as of September 30, 2019, as well as technology access and funding from Novartis and Regeneron, will enable Intellia to fund its anticipated operating expenses and capital expenditure requirements into the second half of 2021. This expectation excludes any potential milestone payments or extension fees that could be earned and distributed under the collaboration agreements withNovartisand Regeneron or any strategic use of capital not currently in the Companys base-case planning assumptions.

Conference Call to Discuss Third Quarter 2019 Earnings

The Company will discuss these results on a conference call today, October 31, 2019, at 8 a.m. ET.

To join the call:

A replay of the call will be available through the Events and Presentations page of the Investor Relations section on Intellias website, beginning on October 31, 2019 at 12 p.m. ET.

About Intellia Therapeutics

Intellia Therapeutics is a leading genome editing company focused on developing curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course, and through improved cell therapies that can treat cancer and immunological diseases, or can replace patients diseased cells. The combination of deep scientific, technical and clinical development experience, along with its leading intellectual property portfolio, puts Intellia in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create a new class of therapeutic products. Learn more about Intellia Therapeutics and CRISPR/Cas9 at intelliatx.com and follow us on Twitter @intelliatweets.

Forward-Looking Statements

This press release contains forward-looking statements of Intellia Therapeutics, Inc. (Intellia or the Company) within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements regarding Intellias beliefs and expectations regarding its planned submission of an investigational new drug (IND) application for NTLA-2001 for the treatment of transthyretin amyloidosis (ATTR) in mid-2020; its plans to nominate a first T cell receptor (TCR)-directed engineered cell therapy development candidate for its acute myeloid leukemia (AML) program by the end of 2019; its plans to advance and complete preclinical studies, including non-human primate studies for its ATTR program, AML program and other in vivo and ex vivo programs; develop our proprietary LNP-AAV hybrid delivery system to advance our complex genome editing capabilities, such as gene insertion; its presentation of additional data at upcoming scientific conferences, and other preclinical data by the end of 2019; the advancement and expansion of its CRISPR/Cas9 technology to develop human therapeutic products, as well as maintain and expand its related intellectual property portfolio; the ability to demonstrate its platforms modularity and replicate or apply results achieved in preclinical studies, including those in its ATTR and AML programs, in any future studies, including human clinical trials; its ability to develop other in vivo orex vivocell therapeutics of all types, and those targeting WT1 in AML in particular, using CRISPR/Cas9 technology; the ability to continue its growth and realize the anticipated contribution of the members of its board of directors and executives to its operations and progress; the impact of its collaborations on its development programs, including but not limited to its collaborations with Regeneron Pharmaceuticals, Inc. and Novartis Institutes for BioMedical Research; statements regarding the timing of regulatory filings regarding its development programs; its use of capital, including ATM receivables, expenses, future accumulated deficit and other financial results during the third quarter of 2019; and the ability to fund operations into the second half of 2021.

Any forward-looking statements in this press release are based on managements current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: risks related to Intellias ability to protect and maintain our intellectual property position, including through our arbitration proceedings against Caribou; risks related to Intellias relationship with third parties, including our licensors; risks related to the ability of our licensors to protect and maintain their intellectual property position; uncertainties related to the initiation and conduct of studies and other development requirements for our product candidates; the risk that any one or more of Intellias product candidates will not be successfully developed and commercialized; the risk that the results of preclinical studies or clinical studies will not be predictive of future results in connection with future studies; the risk that Novartis will not continue to pursue programs it has selected through its collaboration with Intellia; and the risk that Intellias collaborations withNovartisor Regeneron or its otherex vivo collaborations will not continue or will not be successful. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause Intellias actual results to differ from those contained in the forward-looking statements, see the section entitled Risk Factors in Intellias most recent annual report on Form 10-K as well as discussions of potential risks, uncertainties, and other important factors in Intellias other filings with theSecurities and Exchange Commission. All information in this press release is as of the date of the release, andIntellia undertakes no duty to update this information unless required by law.

Intellia Contacts:

Investors:Lina LiAssociate DirectorInvestor Relations+1 857-706-1612lina.li@intelliatx.com

Media:Jennifer Mound SmoterSenior Vice PresidentExternal Affairs & Communications+1 857-706-1071jenn.smoter@intelliatx.com

Continue reading here:
Intellia Therapeutics Announces Third Quarter 2019 Financial Results - GlobeNewswire

Recommendation and review posted by Bethany Smith

We will be contrasting the differences between Proteostasis Therapeutics Inc. (NASDAQ:PTI) and Abeona Therapeutics Inc. (NASDAQ:ABEO) as far as dividends, analyst recommendations, profitability, risk, institutional ownership, earnings and valuation are concerned. The two businesses are rivals in the Biotechnology industry.

Earnings & Valuation

Table 1 shows the gross revenue, earnings per share and valuation for Proteostasis Therapeutics Inc. and Abeona Therapeutics Inc.

Profitability

Table 2 provides us Proteostasis Therapeutics Inc. and Abeona Therapeutics Inc.s return on equity, return on assets and net margins.

Volatility and Risk

Proteostasis Therapeutics Inc.s volatility measures that its 171.00% less volatile than Standard and Poors 500 due to its -0.71 beta. From a competition point of view, Abeona Therapeutics Inc. has a 1.84 beta which is 84.00% more volatile compared to Standard and Poors 500.

Liquidity

The Current Ratio and Quick Ratio of Proteostasis Therapeutics Inc. are 11.3 and 11.3 respectively. Its competitor Abeona Therapeutics Inc.s Current Ratio is 3.3 and its Quick Ratio is 3.3. Proteostasis Therapeutics Inc. can pay off short and long-term obligations better than Abeona Therapeutics Inc.

Analyst Recommendations

The next table highlights the given recommendations and ratings for Proteostasis Therapeutics Inc. and Abeona Therapeutics Inc.

Abeona Therapeutics Inc. on the other hand boasts of a $12.33 consensus target price and a 387.35% potential upside.

Institutional & Insider Ownership

Roughly 60.5% of Proteostasis Therapeutics Inc. shares are owned by institutional investors while 64.4% of Abeona Therapeutics Inc. are owned by institutional investors. Insiders owned roughly 0.3% of Proteostasis Therapeutics Inc.s shares. Competitively, 0.3% are Abeona Therapeutics Inc.s share owned by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year Proteostasis Therapeutics Inc.s stock price has bigger decline than Abeona Therapeutics Inc.

Summary

Abeona Therapeutics Inc. beats on 6 of the 10 factors Proteostasis Therapeutics Inc.

Proteostasis Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics that treat diseases caused by dysfunctional protein processing, such as cystic fibrosis. Its lead product candidate is PTI-428, an orally bioavailable cystic fibrosis transmembrane conductance regulator modulator belonging to the amplifier class that is in Phase-I studies. The company is also developing PTI-801, a corrector molecule; PTI-808, a potentiator molecule; and unfolded protein response (UPR) modulators that are in preclinical development. It has collaboration with Astellas Pharma, Inc. to research and identify therapies targeting the Unfolded Protein Response (UPR) pathway. The company was formerly known as Proteoguard, Inc. and changed its name to Proteostasis Therapeutics, Inc. in September 2007. Proteostasis Therapeutics, Inc. was founded in 2006 and is headquartered in Cambridge, Massachusetts.

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases. The companys lead programs are ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B; and ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A. It is also developing EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); EB-201 for for epidermolysis bullosa (EB); ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; ABO-301, an AAV-based gene therapy for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. In addition, the company is developing plasma-based protein therapy pipeline, including SDF Alpha, an alpha-1 protease inhibitor for inherited COPD using its proprietary salt diafiltration ethanol-free process. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

The rest is here:
Reviewing Proteostasis Therapeutics Inc. (PTI)'s and Abeona Therapeutics Inc. (NASDAQ:ABEO)'s results - MS Wkly

Recommendation and review posted by Bethany Smith

The BLOOD CANCER DRUGS market research report added by Report Ocean, is an in-depth analysis of the latest trends, market size, status, upcoming technologies, industry drivers, challenges, regulatory policies, with key company profiles and strategies of players. The research study provides market introduction, BLOOD CANCER DRUGS market definition, regional market scope, sales and revenue by region, manufacturing cost analysis, Industrial Chain, market effect factors analysis, BLOOD CANCER DRUGS market size forecast, 100+ market data, Tables, Pie Chart, Graphs and Figures, and many more for business intelligence.

The global blood cancer drugs market is anticipated to reach USD 55.6 billion by 2025.

UPTO 30% OFF ON SINGLE USER PDF: https://www.reportocean.com/industry-verticals/sample-request.php?report_id=5256

In the BLOOD CANCER DRUGS Market, some of the major companies are:

Johnson & Johnson Inc., Amgen Inc., Bayer AG., Pfizer, Inc., AbbVie Inc., Roche Holding AG., Celgene Corporation, AstraZeneca, Novartis AG, GlaxoSmithKline PLC, Merck & Co., Inc., and Eli Lily & Co. among others.

The report consists of various chapters and company profiling is a major among them. Company profiling garners business intelligence and track key elements of a business, such as:

BLOOD CANCER DRUGS Market: Insights

The global blood cancer drugs market is anticipated to reach USD 55.6 billion by 2025. The demand for blood cancer drug is primarily driven by growing death incidences by blood cancer, and continuous innovation for developing novel treatments with the help of several ongoing clinical trials. Moreover, increasing research and development of biological and targeted therapies as treatment will spur the blood cancer drugs market during the upcoming period. However, the high price of drugs and the stringent government policies will limit the growth of blood cancer drugs market during the forecast period.

Most of the blood cancers start in the bone marrow, where blood is produced. In blood cancer the growth of normal blood cells is dislodged by the uncontrollable growth of abnormal blood cells. These cancerous cells prevent the blood from performing many of its functions. Hence, the existing treatments of blood cancer are being the foundation for developing the new drugs. The steady flow of the blood cancer drugs has created opportunity for research and development in the existing market. For instance, Amgen Inc. received approval for BLINCYTO in July 2017, which is used in treating B-cell precursor Acute Lymphoblastic leukemia. Similarly, European blood cancer drugs market witnessed the approvals of Gazyvaro, by Roche AG that is used in treating advanced follicular lymphoma. Also, novel technologies like CAR-T are likely to be launched this year.

The global blood cancer drugs market is segmented into blood cancer type, drugs and treatment approaches. On the basis of blood cancer type, the global blood cancer drugs market is segmented into leukemia, lymphoma and myeloma. The lymphoma segment is expected to drive the majority market of blood cancer drugs followed by leukemia. The global market of this segment is primarily driven by the increasing prevalence of lymphoma, and presence of effective treatments in the market. On the basis of drugs, the global blood cancer drugs market is further categorized into Rituaxan/Mabthera (Rituximab), Gleevac/Glivec (Imatinib), Revlimid (Lenalidomide), Velcade (Bortezomib), Tasigna (Nilotinib), Pomalyst (Pomalidomide), Vidaza (Azacitidine), Kyprolis (Carfilzomib), Adcetris (Brentuximab Vedotin), and Others. This continuous innovation for treating various sub-types of blood cancers has led to the development of novel types of treatments. For instance, the combination of Revlimid and Velcade has emerged as the preferential drugs in trials for treating multiple myeloma.

On the basis of treatment approaches the global blood cancer drugs market is further segmented into Chemotherapeutic, mAbs/Targeted Therapies, and Immunotherapeutic. Due to availability of variety of chemotherapeutic agent in the market chemotherapeutic drugs are expected to hold the higher share in blood cancer drugs market. Moreover, their effectiveness for the treatment of blood cancer and increasing number of cancer patients globally has garnered more demand for chemotherapeutic drugs throughout the world.

Geographically, the global blood cancer drugs market is segmented into North America, Europe, Asia Pacific, and the rest of the world. North America dominates the blood cancer drugs market which is followed by Europe and Asia Pacific. Favorable reimbursement policies, surge in R&D investments of various companies, as well as the increase in the number of blood cancer treatments are some of the major factors responsible for the growth of North Americas blood cancer drugs market. Moreover, Asia-Pacific region has been identified as the lucrative market for the for blood cancer drugs due to increasing awareness of the use of these drugs, increased healthcare expenditure, and rising per capita disposable income. These are some of the major factors which are influencing the growth of the blood cancer drugs in Asia-pacific region.

The leading companies operating in this industry include Johnson & Johnson Inc., Amgen Inc., Bayer AG., Pfizer, Inc., AbbVie Inc., Roche Holding AG., Celgene Corporation, AstraZeneca, Novartis AG, GlaxoSmithKline PLC, Merck & Co., Inc., and Eli Lily & Co. among others.

Key Findings from the study suggest blood cancer drugs in the market are much innovative and manufacturers are progressively concentrating on innovation of combination drugs. Companies are in a stage of development of new drugs in order to provide novel treatments for blood cancer. The immunotherapy segment is anticipated to grow at a high growth rate over the forecast period. The growth of this segment is primarily driven by increased awareness for its use as an alternative and effective treatment for blood cancer. North America is presumed to dominate the global blood cancer drugs market over the forecast period. Asia Pacific region which shows signs of high growth potential owing to the booming economies of India, and China.

Get a Sample Report for more Expert and Official insights: @https://www.reportocean.com/industry-verticals/sample-request.php?report_id=5256

The Global BLOOD CANCER DRUGS Market is segmented into various sub-groups to understand the market scenario in detail, the market segmentation are as follows:

[By Blood Cancer Type (Leukemia (Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia), Lymphoma (Hodgkin Lymphoma, Non-Hodgkin Lymphoma (B-Cell Lymphoma, T-Cell Lymphoma)), and Myeloma; By Drugs (Rituaxan/Mabthera (Rituximab), Gleevac/Glivec (Imatinib), Revlimid (Lenalidomide), Velcade (Bortezomib), Tasigna (Nilotinib), Pomalyst (Pomalidomide), Vidaza (Azacitidine), Kyprolis (Carfilzomib), Adcetris (Brentuximab Vedotin), and Others); By Treatment Approaches (Chemotherapeutic, mAbs/Targeted Therapies, and Immunotherapeutic); By Region]

Furthermore, the years considered for the study are as follows:

Historical year 2013-2017

Base year 2018

Forecast period** 2019 to 2025 [** unless otherwise stated]

Regional split of the Global BLOOD CANCER DRUGS Market research report is as follows:

The market research study offers in-depth regional analysis along with the current market scenarios. The major regions analyzed in the study are:

Key highlights and important features of the Report:

Overview and highlights of product and application segments of the global BLOOD CANCER DRUGS Market are provided. Highlights of the segmentation study include price, revenue, sales, sales growth rate, and market share by product.

Explore about Sales data of key players of the global BLOOD CANCER DRUGS Market as well as some useful information on their business. It talks about the gross margin, price, revenue, products, and their specifications, type, applications, competitors, manufacturing base, and the main business of key players operating in the BLOOD CANCER DRUGS Market.

Explore about gross margin, sales, revenue, production, market share, CAGR, and market size by region.

Describe BLOOD CANCER DRUGS Market Findings and Conclusion, Appendix, methodology and data source;

Research Methodology:

The market research was done by adopting various tools under the category of primary and secondary research. For primary research, experts and major sources of information have been interviewed from suppliers side and industries, to obtain and verify the data related to the study of the Global BLOOD CANCER DRUGS Market. In secondary research methodology, various secondary sources were referred to collect and identify extensive piece of information, such as paid databases, directories and annual reports and databases for commercial study of the Global BLOOD CANCER DRUGS Market. Moreover, other secondary sources include studying technical papers, news releases, government websites, product literatures, white papers, and other literatures to research the market in detail.

Browse Premium Research Report with Tables and Figures at @ https://www.reportocean.com/industry-verticals/details?report_id=5256

There are 15 Chapters to display the Global BLOOD CANCER DRUGS Market:

Chapter 1, to describe Definition, Specifications and Classification of Global BLOOD CANCER DRUGS, Applications of, Market Segment by Regions;Chapter 2, to analyze the Manufacturing Cost Structure, Raw Material and Suppliers, Manufacturing Process, Industry Chain Structure;Chapter 3, to display the Technical Data and Manufacturing Plants Analysis of , Capacity and Commercial Production Date, Manufacturing Plants Distribution, Export & Import, R&D Status and Technology Source, Raw Materials Sources Analysis;Chapter 4, to show the Overall Market Analysis, Capacity Analysis (Company Segment), Sales Analysis (Company Segment), Sales Price Analysis (Company Segment);Chapter 5 and 6, to show the Regional Market Analysis that includes United States, EU, Japan, China, India & Southeast Asia, Segment Market Analysis (by Type);Chapter 7 and 8, to explore the Market Analysis by Application Major Manufacturers Analysis;Chapter 9, Market Trend Analysis, Regional Market Trend, Market Trend by Product Type, Market Trend by Application;Chapter 10, Regional Marketing Type Analysis, International Trade Type Analysis, Supply Chain Analysis;Chapter 11, to analyze the Consumers Analysis of Global BLOOD CANCER DRUGS by region, type and application;Chapter 12, to describe BLOOD CANCER DRUGS Research Findings and Conclusion, Appendix, methodology and data source;Chapter 13, 14 and 15, to describe BLOOD CANCER DRUGS sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source.

About Report Ocean:

We are the best market research reports provider in the industry. Report Ocean believe in providing the quality reports to clients to meet the top line and bottom line goals which will boost your market share in todays competitive environment. Report Ocean is one-stop solution for individuals, organizations, and industries that are looking for innovative market research reports.

Get in Touch with Us:

Name: Varda

Email: [emailprotected]

Address: Classic Tower, Rajnagar Extension, Ghaziabad, 201017 India

Tel: +1 888 212 3539 (US TOLL FREE)

Website: https://www.reportocean.com/

See the original post:
In Vitro Fertilization (IVF) Services Market to Witness Exponential Growth by 2023 - Health News Office

Recommendation and review posted by Bethany Smith

The BLOOD CANCER DRUGS market research report added by Report Ocean, is an in-depth analysis of the latest trends, market size, status, upcoming technologies, industry drivers, challenges, regulatory policies, with key company profiles and strategies of players. The research study provides market introduction, BLOOD CANCER DRUGS market definition, regional market scope, sales and revenue by region, manufacturing cost analysis, Industrial Chain, market effect factors analysis, BLOOD CANCER DRUGS market size forecast, 100+ market data, Tables, Pie Chart, Graphs and Figures, and many more for business intelligence.

The global blood cancer drugs market is anticipated to reach USD 55.6 billion by 2025.

UPTO 30% OFF ON SINGLE USER PDF: https://www.reportocean.com/industry-verticals/sample-request.php?report_id=5256

In the BLOOD CANCER DRUGS Market, some of the major companies are:

Johnson & Johnson Inc., Amgen Inc., Bayer AG., Pfizer, Inc., AbbVie Inc., Roche Holding AG., Celgene Corporation, AstraZeneca, Novartis AG, GlaxoSmithKline PLC, Merck & Co., Inc., and Eli Lily & Co. among others.

The report consists of various chapters and company profiling is a major among them. Company profiling garners business intelligence and track key elements of a business, such as:

BLOOD CANCER DRUGS Market: Insights

The global blood cancer drugs market is anticipated to reach USD 55.6 billion by 2025. The demand for blood cancer drug is primarily driven by growing death incidences by blood cancer, and continuous innovation for developing novel treatments with the help of several ongoing clinical trials. Moreover, increasing research and development of biological and targeted therapies as treatment will spur the blood cancer drugs market during the upcoming period. However, the high price of drugs and the stringent government policies will limit the growth of blood cancer drugs market during the forecast period.

Most of the blood cancers start in the bone marrow, where blood is produced. In blood cancer the growth of normal blood cells is dislodged by the uncontrollable growth of abnormal blood cells. These cancerous cells prevent the blood from performing many of its functions. Hence, the existing treatments of blood cancer are being the foundation for developing the new drugs. The steady flow of the blood cancer drugs has created opportunity for research and development in the existing market. For instance, Amgen Inc. received approval for BLINCYTO in July 2017, which is used in treating B-cell precursor Acute Lymphoblastic leukemia. Similarly, European blood cancer drugs market witnessed the approvals of Gazyvaro, by Roche AG that is used in treating advanced follicular lymphoma. Also, novel technologies like CAR-T are likely to be launched this year.

The global blood cancer drugs market is segmented into blood cancer type, drugs and treatment approaches. On the basis of blood cancer type, the global blood cancer drugs market is segmented into leukemia, lymphoma and myeloma. The lymphoma segment is expected to drive the majority market of blood cancer drugs followed by leukemia. The global market of this segment is primarily driven by the increasing prevalence of lymphoma, and presence of effective treatments in the market. On the basis of drugs, the global blood cancer drugs market is further categorized into Rituaxan/Mabthera (Rituximab), Gleevac/Glivec (Imatinib), Revlimid (Lenalidomide), Velcade (Bortezomib), Tasigna (Nilotinib), Pomalyst (Pomalidomide), Vidaza (Azacitidine), Kyprolis (Carfilzomib), Adcetris (Brentuximab Vedotin), and Others. This continuous innovation for treating various sub-types of blood cancers has led to the development of novel types of treatments. For instance, the combination of Revlimid and Velcade has emerged as the preferential drugs in trials for treating multiple myeloma.

On the basis of treatment approaches the global blood cancer drugs market is further segmented into Chemotherapeutic, mAbs/Targeted Therapies, and Immunotherapeutic. Due to availability of variety of chemotherapeutic agent in the market chemotherapeutic drugs are expected to hold the higher share in blood cancer drugs market. Moreover, their effectiveness for the treatment of blood cancer and increasing number of cancer patients globally has garnered more demand for chemotherapeutic drugs throughout the world.

Geographically, the global blood cancer drugs market is segmented into North America, Europe, Asia Pacific, and the rest of the world. North America dominates the blood cancer drugs market which is followed by Europe and Asia Pacific. Favorable reimbursement policies, surge in R&D investments of various companies, as well as the increase in the number of blood cancer treatments are some of the major factors responsible for the growth of North Americas blood cancer drugs market. Moreover, Asia-Pacific region has been identified as the lucrative market for the for blood cancer drugs due to increasing awareness of the use of these drugs, increased healthcare expenditure, and rising per capita disposable income. These are some of the major factors which are influencing the growth of the blood cancer drugs in Asia-pacific region.

The leading companies operating in this industry include Johnson & Johnson Inc., Amgen Inc., Bayer AG., Pfizer, Inc., AbbVie Inc., Roche Holding AG., Celgene Corporation, AstraZeneca, Novartis AG, GlaxoSmithKline PLC, Merck & Co., Inc., and Eli Lily & Co. among others.

Key Findings from the study suggest blood cancer drugs in the market are much innovative and manufacturers are progressively concentrating on innovation of combination drugs. Companies are in a stage of development of new drugs in order to provide novel treatments for blood cancer. The immunotherapy segment is anticipated to grow at a high growth rate over the forecast period. The growth of this segment is primarily driven by increased awareness for its use as an alternative and effective treatment for blood cancer. North America is presumed to dominate the global blood cancer drugs market over the forecast period. Asia Pacific region which shows signs of high growth potential owing to the booming economies of India, and China.

Get a Sample Report for more Expert and Official insights: @https://www.reportocean.com/industry-verticals/sample-request.php?report_id=5256

The Global BLOOD CANCER DRUGS Market is segmented into various sub-groups to understand the market scenario in detail, the market segmentation are as follows:

[By Blood Cancer Type (Leukemia (Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia), Lymphoma (Hodgkin Lymphoma, Non-Hodgkin Lymphoma (B-Cell Lymphoma, T-Cell Lymphoma)), and Myeloma; By Drugs (Rituaxan/Mabthera (Rituximab), Gleevac/Glivec (Imatinib), Revlimid (Lenalidomide), Velcade (Bortezomib), Tasigna (Nilotinib), Pomalyst (Pomalidomide), Vidaza (Azacitidine), Kyprolis (Carfilzomib), Adcetris (Brentuximab Vedotin), and Others); By Treatment Approaches (Chemotherapeutic, mAbs/Targeted Therapies, and Immunotherapeutic); By Region]

Furthermore, the years considered for the study are as follows:

Historical year 2013-2017

Base year 2018

Forecast period** 2019 to 2025 [** unless otherwise stated]

Regional split of the Global BLOOD CANCER DRUGS Market research report is as follows:

The market research study offers in-depth regional analysis along with the current market scenarios. The major regions analyzed in the study are:

Key highlights and important features of the Report:

Overview and highlights of product and application segments of the global BLOOD CANCER DRUGS Market are provided. Highlights of the segmentation study include price, revenue, sales, sales growth rate, and market share by product.

Explore about Sales data of key players of the global BLOOD CANCER DRUGS Market as well as some useful information on their business. It talks about the gross margin, price, revenue, products, and their specifications, type, applications, competitors, manufacturing base, and the main business of key players operating in the BLOOD CANCER DRUGS Market.

Explore about gross margin, sales, revenue, production, market share, CAGR, and market size by region.

Describe BLOOD CANCER DRUGS Market Findings and Conclusion, Appendix, methodology and data source;

Research Methodology:

The market research was done by adopting various tools under the category of primary and secondary research. For primary research, experts and major sources of information have been interviewed from suppliers side and industries, to obtain and verify the data related to the study of the Global BLOOD CANCER DRUGS Market. In secondary research methodology, various secondary sources were referred to collect and identify extensive piece of information, such as paid databases, directories and annual reports and databases for commercial study of the Global BLOOD CANCER DRUGS Market. Moreover, other secondary sources include studying technical papers, news releases, government websites, product literatures, white papers, and other literatures to research the market in detail.

Browse Premium Research Report with Tables and Figures at @ https://www.reportocean.com/industry-verticals/details?report_id=5256

There are 15 Chapters to display the Global BLOOD CANCER DRUGS Market:

Chapter 1, to describe Definition, Specifications and Classification of Global BLOOD CANCER DRUGS, Applications of, Market Segment by Regions;Chapter 2, to analyze the Manufacturing Cost Structure, Raw Material and Suppliers, Manufacturing Process, Industry Chain Structure;Chapter 3, to display the Technical Data and Manufacturing Plants Analysis of , Capacity and Commercial Production Date, Manufacturing Plants Distribution, Export & Import, R&D Status and Technology Source, Raw Materials Sources Analysis;Chapter 4, to show the Overall Market Analysis, Capacity Analysis (Company Segment), Sales Analysis (Company Segment), Sales Price Analysis (Company Segment);Chapter 5 and 6, to show the Regional Market Analysis that includes United States, EU, Japan, China, India & Southeast Asia, Segment Market Analysis (by Type);Chapter 7 and 8, to explore the Market Analysis by Application Major Manufacturers Analysis;Chapter 9, Market Trend Analysis, Regional Market Trend, Market Trend by Product Type, Market Trend by Application;Chapter 10, Regional Marketing Type Analysis, International Trade Type Analysis, Supply Chain Analysis;Chapter 11, to analyze the Consumers Analysis of Global BLOOD CANCER DRUGS by region, type and application;Chapter 12, to describe BLOOD CANCER DRUGS Research Findings and Conclusion, Appendix, methodology and data source;Chapter 13, 14 and 15, to describe BLOOD CANCER DRUGS sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source.

About Report Ocean:

We are the best market research reports provider in the industry. Report Ocean believe in providing the quality reports to clients to meet the top line and bottom line goals which will boost your market share in todays competitive environment. Report Ocean is one-stop solution for individuals, organizations, and industries that are looking for innovative market research reports.

Get in Touch with Us:

Name: Varda

Email: [emailprotected]

Address: Classic Tower, Rajnagar Extension, Ghaziabad, 201017 India

Tel: +1 888 212 3539 (US TOLL FREE)

Website: https://www.reportocean.com/

Visit link:
Designer and Luxury Footwear Market to Witness Robust Expansion throughout the Forecast 2018-2023 - Health News Office

Recommendation and review posted by Bethany Smith

Analysts predict that Axovant Gene Therapies Ltd (NASDAQ:AXGT) will announce earnings per share (EPS) of ($1.15) for the current quarter, according to Zacks. Zero analysts have made estimates for Axovant Gene Therapies earnings. The lowest EPS estimate is ($1.39) and the highest is ($0.76). Axovant Gene Therapies posted earnings per share of ($2.24) during the same quarter last year, which indicates a positive year-over-year growth rate of 48.7%. The company is scheduled to report its next quarterly earnings results on Wednesday, November 6th.

According to Zacks, analysts expect that Axovant Gene Therapies will report full-year earnings of ($4.25) per share for the current fiscal year, with EPS estimates ranging from ($5.59) to ($3.47). For the next fiscal year, analysts expect that the company will report earnings of ($3.32) per share, with EPS estimates ranging from ($4.35) to ($2.89). Zacks earnings per share calculations are an average based on a survey of sell-side analysts that cover Axovant Gene Therapies.

Axovant Gene Therapies (NASDAQ:AXGT) last issued its quarterly earnings data on Friday, August 9th. The company reported ($1.23) EPS for the quarter, topping the consensus estimate of ($1.34) by $0.11.

Several large investors have recently added to or reduced their stakes in AXGT. BlackRock Inc. acquired a new position in shares of Axovant Gene Therapies in the second quarter valued at approximately $1,482,000. Marshall Wace LLP acquired a new position in Axovant Gene Therapies during the first quarter worth $272,000. Jane Street Group LLC grew its holdings in Axovant Gene Therapies by 28.8% during the second quarter. Jane Street Group LLC now owns 46,455 shares of the companys stock worth $289,000 after acquiring an additional 10,375 shares during the period. Finally, Tower Research Capital LLC TRC grew its holdings in Axovant Gene Therapies by 955.3% during the second quarter. Tower Research Capital LLC TRC now owns 4,221 shares of the companys stock worth $27,000 after acquiring an additional 3,821 shares during the period. 13.76% of the stock is currently owned by institutional investors and hedge funds.

Axovant Gene Therapies stock traded down $0.01 during mid-day trading on Thursday, reaching $6.29. 38,700 shares of the companys stock were exchanged, compared to its average volume of 118,874. The company has a fifty day moving average of $6.55 and a 200-day moving average of $5.80. The company has a quick ratio of 1.70, a current ratio of 1.70 and a debt-to-equity ratio of 0.60. The company has a market cap of $143.40 million, a P/E ratio of -0.78 and a beta of 1.25. Axovant Gene Therapies has a twelve month low of $3.81 and a twelve month high of $19.60.

About Axovant Gene Therapies

Axovant Gene Therapies Ltd., a clinical-stage gene therapy company, focuses on developing a pipeline of product candidates for debilitating neurological and neuromuscular diseases. The company's current pipeline of gene therapy candidates targets GM1 gangliosidosis, GM2 gangliosidosis, Parkinson's disease, oculopharyngeal muscular dystrophy, amyotrophic lateral sclerosis, and frontotemporal dementia.

Recommended Story: What are earnings reports?

Get a free copy of the Zacks research report on Axovant Gene Therapies (AXGT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Axovant Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.

See original here:
Axovant Gene Therapies Ltd (NASDAQ:AXGT) Expected to Post Earnings of -$1.15 Per Share - Mitchell Messenger

Recommendation and review posted by Bethany Smith

The BLOOD CANCER DRUGS market research report added by Report Ocean, is an in-depth analysis of the latest trends, market size, status, upcoming technologies, industry drivers, challenges, regulatory policies, with key company profiles and strategies of players. The research study provides market introduction, BLOOD CANCER DRUGS market definition, regional market scope, sales and revenue by region, manufacturing cost analysis, Industrial Chain, market effect factors analysis, BLOOD CANCER DRUGS market size forecast, 100+ market data, Tables, Pie Chart, Graphs and Figures, and many more for business intelligence.

The global blood cancer drugs market is anticipated to reach USD 55.6 billion by 2025.

UPTO 30% OFF ON SINGLE USER PDF: https://www.reportocean.com/industry-verticals/sample-request.php?report_id=5256

In the BLOOD CANCER DRUGS Market, some of the major companies are:

Johnson & Johnson Inc., Amgen Inc., Bayer AG., Pfizer, Inc., AbbVie Inc., Roche Holding AG., Celgene Corporation, AstraZeneca, Novartis AG, GlaxoSmithKline PLC, Merck & Co., Inc., and Eli Lily & Co. among others.

The report consists of various chapters and company profiling is a major among them. Company profiling garners business intelligence and track key elements of a business, such as:

BLOOD CANCER DRUGS Market: Insights

The global blood cancer drugs market is anticipated to reach USD 55.6 billion by 2025. The demand for blood cancer drug is primarily driven by growing death incidences by blood cancer, and continuous innovation for developing novel treatments with the help of several ongoing clinical trials. Moreover, increasing research and development of biological and targeted therapies as treatment will spur the blood cancer drugs market during the upcoming period. However, the high price of drugs and the stringent government policies will limit the growth of blood cancer drugs market during the forecast period.

Most of the blood cancers start in the bone marrow, where blood is produced. In blood cancer the growth of normal blood cells is dislodged by the uncontrollable growth of abnormal blood cells. These cancerous cells prevent the blood from performing many of its functions. Hence, the existing treatments of blood cancer are being the foundation for developing the new drugs. The steady flow of the blood cancer drugs has created opportunity for research and development in the existing market. For instance, Amgen Inc. received approval for BLINCYTO in July 2017, which is used in treating B-cell precursor Acute Lymphoblastic leukemia. Similarly, European blood cancer drugs market witnessed the approvals of Gazyvaro, by Roche AG that is used in treating advanced follicular lymphoma. Also, novel technologies like CAR-T are likely to be launched this year.

The global blood cancer drugs market is segmented into blood cancer type, drugs and treatment approaches. On the basis of blood cancer type, the global blood cancer drugs market is segmented into leukemia, lymphoma and myeloma. The lymphoma segment is expected to drive the majority market of blood cancer drugs followed by leukemia. The global market of this segment is primarily driven by the increasing prevalence of lymphoma, and presence of effective treatments in the market. On the basis of drugs, the global blood cancer drugs market is further categorized into Rituaxan/Mabthera (Rituximab), Gleevac/Glivec (Imatinib), Revlimid (Lenalidomide), Velcade (Bortezomib), Tasigna (Nilotinib), Pomalyst (Pomalidomide), Vidaza (Azacitidine), Kyprolis (Carfilzomib), Adcetris (Brentuximab Vedotin), and Others. This continuous innovation for treating various sub-types of blood cancers has led to the development of novel types of treatments. For instance, the combination of Revlimid and Velcade has emerged as the preferential drugs in trials for treating multiple myeloma.

On the basis of treatment approaches the global blood cancer drugs market is further segmented into Chemotherapeutic, mAbs/Targeted Therapies, and Immunotherapeutic. Due to availability of variety of chemotherapeutic agent in the market chemotherapeutic drugs are expected to hold the higher share in blood cancer drugs market. Moreover, their effectiveness for the treatment of blood cancer and increasing number of cancer patients globally has garnered more demand for chemotherapeutic drugs throughout the world.

Geographically, the global blood cancer drugs market is segmented into North America, Europe, Asia Pacific, and the rest of the world. North America dominates the blood cancer drugs market which is followed by Europe and Asia Pacific. Favorable reimbursement policies, surge in R&D investments of various companies, as well as the increase in the number of blood cancer treatments are some of the major factors responsible for the growth of North Americas blood cancer drugs market. Moreover, Asia-Pacific region has been identified as the lucrative market for the for blood cancer drugs due to increasing awareness of the use of these drugs, increased healthcare expenditure, and rising per capita disposable income. These are some of the major factors which are influencing the growth of the blood cancer drugs in Asia-pacific region.

The leading companies operating in this industry include Johnson & Johnson Inc., Amgen Inc., Bayer AG., Pfizer, Inc., AbbVie Inc., Roche Holding AG., Celgene Corporation, AstraZeneca, Novartis AG, GlaxoSmithKline PLC, Merck & Co., Inc., and Eli Lily & Co. among others.

Key Findings from the study suggest blood cancer drugs in the market are much innovative and manufacturers are progressively concentrating on innovation of combination drugs. Companies are in a stage of development of new drugs in order to provide novel treatments for blood cancer. The immunotherapy segment is anticipated to grow at a high growth rate over the forecast period. The growth of this segment is primarily driven by increased awareness for its use as an alternative and effective treatment for blood cancer. North America is presumed to dominate the global blood cancer drugs market over the forecast period. Asia Pacific region which shows signs of high growth potential owing to the booming economies of India, and China.

Get a Sample Report for more Expert and Official insights: @https://www.reportocean.com/industry-verticals/sample-request.php?report_id=5256

The Global BLOOD CANCER DRUGS Market is segmented into various sub-groups to understand the market scenario in detail, the market segmentation are as follows:

[By Blood Cancer Type (Leukemia (Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia), Lymphoma (Hodgkin Lymphoma, Non-Hodgkin Lymphoma (B-Cell Lymphoma, T-Cell Lymphoma)), and Myeloma; By Drugs (Rituaxan/Mabthera (Rituximab), Gleevac/Glivec (Imatinib), Revlimid (Lenalidomide), Velcade (Bortezomib), Tasigna (Nilotinib), Pomalyst (Pomalidomide), Vidaza (Azacitidine), Kyprolis (Carfilzomib), Adcetris (Brentuximab Vedotin), and Others); By Treatment Approaches (Chemotherapeutic, mAbs/Targeted Therapies, and Immunotherapeutic); By Region]

Furthermore, the years considered for the study are as follows:

Historical year 2013-2017

Base year 2018

Forecast period** 2019 to 2025 [** unless otherwise stated]

Regional split of the Global BLOOD CANCER DRUGS Market research report is as follows:

The market research study offers in-depth regional analysis along with the current market scenarios. The major regions analyzed in the study are:

Key highlights and important features of the Report:

Overview and highlights of product and application segments of the global BLOOD CANCER DRUGS Market are provided. Highlights of the segmentation study include price, revenue, sales, sales growth rate, and market share by product.

Explore about Sales data of key players of the global BLOOD CANCER DRUGS Market as well as some useful information on their business. It talks about the gross margin, price, revenue, products, and their specifications, type, applications, competitors, manufacturing base, and the main business of key players operating in the BLOOD CANCER DRUGS Market.

Explore about gross margin, sales, revenue, production, market share, CAGR, and market size by region.

Describe BLOOD CANCER DRUGS Market Findings and Conclusion, Appendix, methodology and data source;

Research Methodology:

The market research was done by adopting various tools under the category of primary and secondary research. For primary research, experts and major sources of information have been interviewed from suppliers side and industries, to obtain and verify the data related to the study of the Global BLOOD CANCER DRUGS Market. In secondary research methodology, various secondary sources were referred to collect and identify extensive piece of information, such as paid databases, directories and annual reports and databases for commercial study of the Global BLOOD CANCER DRUGS Market. Moreover, other secondary sources include studying technical papers, news releases, government websites, product literatures, white papers, and other literatures to research the market in detail.

Browse Premium Research Report with Tables and Figures at @ https://www.reportocean.com/industry-verticals/details?report_id=5256

There are 15 Chapters to display the Global BLOOD CANCER DRUGS Market:

Chapter 1, to describe Definition, Specifications and Classification of Global BLOOD CANCER DRUGS, Applications of, Market Segment by Regions;Chapter 2, to analyze the Manufacturing Cost Structure, Raw Material and Suppliers, Manufacturing Process, Industry Chain Structure;Chapter 3, to display the Technical Data and Manufacturing Plants Analysis of , Capacity and Commercial Production Date, Manufacturing Plants Distribution, Export & Import, R&D Status and Technology Source, Raw Materials Sources Analysis;Chapter 4, to show the Overall Market Analysis, Capacity Analysis (Company Segment), Sales Analysis (Company Segment), Sales Price Analysis (Company Segment);Chapter 5 and 6, to show the Regional Market Analysis that includes United States, EU, Japan, China, India & Southeast Asia, Segment Market Analysis (by Type);Chapter 7 and 8, to explore the Market Analysis by Application Major Manufacturers Analysis;Chapter 9, Market Trend Analysis, Regional Market Trend, Market Trend by Product Type, Market Trend by Application;Chapter 10, Regional Marketing Type Analysis, International Trade Type Analysis, Supply Chain Analysis;Chapter 11, to analyze the Consumers Analysis of Global BLOOD CANCER DRUGS by region, type and application;Chapter 12, to describe BLOOD CANCER DRUGS Research Findings and Conclusion, Appendix, methodology and data source;Chapter 13, 14 and 15, to describe BLOOD CANCER DRUGS sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source.

About Report Ocean:

We are the best market research reports provider in the industry. Report Ocean believe in providing the quality reports to clients to meet the top line and bottom line goals which will boost your market share in todays competitive environment. Report Ocean is one-stop solution for individuals, organizations, and industries that are looking for innovative market research reports.

Get in Touch with Us:

Name: Varda

Email: [emailprotected]

Address: Classic Tower, Rajnagar Extension, Ghaziabad, 201017 India

Tel: +1 888 212 3539 (US TOLL FREE)

Website: https://www.reportocean.com/

See original here:
Water Heater Market Projected to Garner Significant Revenues by 2025 - Health News Office

Recommendation and review posted by Bethany Smith

Crystal Market Research has recently updated its massive report catalog by adding a fresh study titled Global Autologous Stem Cell Based Therapies Market Report 2019. The Autologous Stem Cell Based Therapies market report presents an analytical study that is defined based on the various parameters and trends followed by the global Autologous Stem Cell Based Therapies market. The report contains the assessment of futuristic growth based on past growth models and currently accompanied by the market. Extensive information on factors entered and market growth forecasts are also included in the market.

Global Autologous Stem Cell Based Therapies Market report provides an in-depth study of industry size, share, trend, opportunities within the latest research report added by CMR. The report consists of market sizes and forecast for the period from 2019 to 2025, and compounded annual growth rate (CAGR%) measured for individual segments and regional markets, competitive landscape of main market players, vital analysis of market dynamics and profiling of key providers collaborating in the Autologous Stem Cell Based Therapies market.

Continue

Get overview of FREE sample report @ https://www.crystalmarketresearch.com/report-sample/HC022437

Read more or inquiry about Autologous Stem Cell Based Therapies research @ https://www.crystalmarketresearch.com/send-an-enquiry/HC022437

Access discount related details @ https://www.crystalmarketresearch.com/check-discount/HC022437

Contacts Us:

Judy | 304 South Jones Blvd, Suite 1896

Las Vegas NV 89107

United States

E-mail:

sales@crystalmarketresearch.com

| Ph: +1-888-213-4282

See the original post:
Latest Released Report on Autologous Stem Cell Based Therapies Market to Witness the Highest Growth Globally in Coming Years: Osiris...

Recommendation and review posted by Bethany Smith

HOUSTON--(BUSINESS WIRE)--InGeneron, Inc., a regenerative medicine and cell therapy company, today announced the publication of promising results in developing a novel treatment for chronic ischemic heart failure using its regenerative cell therapy platform.

A newly-released research paper published in the World Journal of Stem Cells provides missing pieces of evidence for a fundamental change in the treatment of chronic ischemic heart failure, showing efficacy and safety of a novel stem cell treatment in cardiology. Patients with heart failure as a consequence of previous myocardial infarction are a large and currently underserved patient population, due to the lack of regenerative treatment options.

The publication, performed in a pig model for the study of chronic myocardial infarction, evidences for the first time that regeneration of the damaged tissue in the heart - responsible for chronic ischemic heart failure - is possible. Specifically, the study demonstrates that InGenerons fresh, uncultured, autologous adipose derived regenerative cells (UA-ADRCs) - isolated and administered at point of care - provide a significant improvement of cardiac circulatory parameters in chronic ischemic heart failure. The results show that the mean cardiac output increased by 37%, the mean left ventricular mass increased by 29% and the mean relative amount of scar volume of the left ventricular wall decreased by 21% six weeks after treatment with the cells. All results were statistically significant compared to the control group. Notably, on average only 18 gram of adipose tissue were required to recover the averaged 18 million cells injected to achieve the reported effects.

The findings represent an important step in research, laying the foundation for new frontiers on cardiac regeneration of chronic ischemic heart failure in human patients. While previous studies indicated that stem cells (including UA-ADRCs) might be of benefit in acute myocardial infarction, this benchmark had previously not been achieved by studies of autologous stem cells for chronic heart failure following myocardial infarction.

Haenel et al., the authors of the publication, attribute the success of the study to two important improvements over previous attempts. The primary success factor was the use of InGeneron's technology for isolating the stem cells at point of care. In this regard, a recent publication by Winnier et al. (PLoS One 2019;14:e0221457) demonstrated that the technology used (TransposeRT / Matrase; InGeneron, Inc., Houston, TX, USA), provides the highest published number of living, uncultured, autologous, adult pluripotent stem cells recovered per gram of adipose tissue.

The second differentiator to all previously published results for myocardial regeneration is the application method to the damaged heart. Haenel et al. administered the stem cells retrograde through the hearts venous system, precisely to the area in need of regeneration. This retrograde injection technique, combined with a temporary blockage of the coronary vein at the level of a previous arterial occlusion, allowed the stem cells to overcome the endothelial barrier and thereby created a homogenous distribution of injected cells throughout the damaged myocardial tissue.

Dr. Eckhard Alt, Executive Chair of InGeneron, Inc. and senior author of the study, commented "this therapy, which may be performed in an ambulatory setting without the known risks associated with major anticoagulation, delivers the stem cells in about 15 minutes and involves a total treatment time of approximately 3 hours. This gives hope that millions of patients suffering from chronic ischemic heart failure might benefit from rebuilding the heart with their own stem cells".

The study, entitled "Unmodified autologous stem cells at point of care for chronic myocardial infarction", by Haenel et al. was published in the World Journal of Stem Cells on October 26, 2019.

While the company is advancing its ongoing clinical programs for key orthopedic conditions, additional studies are designed to validate the clinical potential of stem cells in patients with coronary artery disease and chronic heart failure.

About InGeneron

InGeneron is a clinical stage cell therapy company enabling novel, safe and evidence-based regenerative medicine therapies. Our purpose is to set new therapeutic standards by developing treatments that unlock the healing potential of each patients own regenerative cells processed at the point of care for same-day application. We focus on helping patients who are impacted by musculoskeletal indications and are pursuing research to extend the application of our platform technology to additional treatment areas.

http://www.ingeneron.com

Go here to see the original:
InGeneron Announces Publication of Preclinical Results for its Cell Therapy in Chronic Ischemic Heart Failure - Business Wire

Recommendation and review posted by Bethany Smith

AUSTIN (KXAN) Many people are looking forward to an extra hour of sleep with the time change Sunday morning as daylight saving comes to an end. However, others may begin to feel the effects of Seasonal Affective Disorder.

Seasonal Affective Disorder (SAD), also know as seasonal depression, is a type of depression that occurs around the same time every year, usually in late fall, and can go through the end of winter when the days become longer again.

While less common, SAD can also occur in the spring and summer time as well.

According to Help Guide, fall and winter SAD symptoms can include low self-esteem, appetite and weight changes, difficulty concentrating and changes in sleeping pattern.

The National Institute of Mental Healthsays women are four times more likely to experience SAD symptoms then men. Living far from the equator, family history of depression and young age can also be risk factors.

While the exact causes of SAD are unknown, researchers have found some biological cues. People with SAD may have trouble regulating serotonin, overproducing the hormone melatonin and lack of vitamin D.

Mayo Clinicsays treatment for SAD can include anything from light therapy to meditation to taking vitamin D supplements.

Remember to set your clocks back and take time to understand how the changing of seasons might lead to changes in your mood.

For more information go toThe National Institute of Mental Health.

LATEST STORIES

Read more:
The time changes on Sunday, but your mood might be changing too - WKRG News 5

Recommendation and review posted by Bethany Smith

DEAR DOCS: I was a cigarette smoker for 30 years until my doctor told me that I needed to quit immediately. So I started vaping. It sure made it easy to walk away from tobacco. But can I use nicotine vapes safely?

DEAR JORDAN: The reason it was easy to go from cigarette to vape is because you were substituting one nicotine source for another. And thats no way to reduce your health risks.

Nicotine is an addictive drug that is associated with increased risk of cardiovascular, respiratory and gastrointestinal disorders, decreased immune response, harm to reproductive health and DNA mutation that leads to cancer. Plus, the American Heart Association says that vapers who think vaping nicotine can help them stop using cigarettes are likely to continue smoking cigarettes while they vape thats called dual use.

Vaping anything has never been safe. The only studies that say theres no harm associated with e-cigarettes are those funded by the vaping (tobacco) industry. The Altria Group (formerly Philip Morris of Marlboro and Virginia Slims fame) recently acquired a 35% stake in Juul. Its an old, familiar bag of tricks. Remember the 50s ad slogan that said, More doctors smoke Camels than any other cigarette?

The Centers for Disease Control and Prevention has reported that as of this writing more than 1,080 people have developed lung illnesses and at least 19 people have died from vaping. Those numbers could be just the tip of the iceberg. Lung damage from vaping isnt associated only with THC; nicotine also has been a cause. According to Mayo Clinic doctors, vaping-induced lung injury looks like a toxic chemical exposure, a toxic chemical fume exposure or a chemical burn injury. Thats because vaping is a delivery system for flavorings, ultrafine particles, heavy metals and volatile organic compounds.

So go to http://www.heart.org and type in 5 Steps to Quit (it includes vaping). For more comprehensive program, talk to your doctor.

DEAR DOCS:: Ive been waking up grumpy lately, and I dont know why. Im usually fine by midday. What can I do when I wake up to set myself up for a good mood in the morning?

DEAR CHONDRA: Lots of people wake up feeling grumpy at least a couple of days a week. In fact, one shower company in Great Britain did a survey and found that 6 out of 10 Brits wake up in a bad mood. The shower companys solution? Take a shower!

Well, we agree, but to maintain that good mood throughout the morning and rest of the day, you need to provide your body with the nutrition it needs to smoothly regulate your hormones, gut function and brain power. That means eating a nutritious breakfast. Your best bet is to put together a protein- and fiber-filled first meal of the day.

A great choice is oatmeal, muesli or granola (100% whole grains) with nonfat yogurt and lots of strawberries, blueberries and/or raspberries. Whole grains digest slowly and steadily raise levels of your feel-good hormone serotonin. They also help to keep your blood sugar stable, which improves mood.

Fresh berries deliver polyphenols, which can help you moderate your stress response and improve heart health. For variety, you can try grapefruit, oranges and melons (honeydew and cantaloupe).

Low-fat yogurt can deliver about a third of your daily requirement for calcium, which is good for your blood pressure and (along with magnesium) can have an anti-anxiety effect.

You might also try these foods that deliver mood-enhancing benefits: whole-wheat avocado toast; an egg-white omelet with vegetables; a green smoothie; or almond oatmeal. All those recipes and more are available at sharecare.com or doctoroz.com.

Other mood enhancers: Go to bed an hour earlier and get up an hour earlier. Get plenty of physical activity (sex counts); thatll stimulate the release of oxytocin, which increases your happiness. All these choices may help you see a turnaround in your morning mood.

Mehmet Oz, M.D., is host of The Dr. Oz Show. Mike Roizen, M.D., is chief wellness officer and chairman of Wellness Institute at Cleveland Clinic. Email questions to youdocsdaily@sharecare.com.

See the article here:
Drs. Oz & Roizen: Respiratory effects of vaping; foods to keep you happy all day - The Union Leader

Recommendation and review posted by Bethany Smith

This transcript has been edited for clarity.

Good morning, everyone. I'm Dr Kathy Miller from Indiana University, and I'm here to tell you a story.

On a good day, God made a mixture of passion, determination, and smarts, and he called that mixture Bernie. Those of us in the breast cancer world know that Bernie can only mean Dr Bernard Fisher, who left us not long ago after 101 amazing years on this earth.

Very early in my training, I remember asking a mentor why breast cancer seemed like it had advanced faster than colon cancer or lung cancer. Was it that the biology of the disease was more favorable? Did we have an easier tumor? He laughed and said, "Maybe, but really it's because we have Bernie."

What he meant is that we had Berniewe had a surgeon who was passionate about research.

Bernie was famous for reminding us all that in God we trust; everybody else has to have data. You don't assume things that you can proveyou get the data. For Bernie, the data often started in the basic laboratory but continued into the clinic.

He was passionate about the role of clinical research and challenging the surgical dogma that had existed for 50 years. Only someone with incredible smarts, determination, and passionthat force of naturewould have been able to mount those early studies, gradually moving from radical mastectomy to modified radical mastectomy to lumpectomy to sentinel node biopsy.

Bernie was an early champion of the role of systemic therapy, making us all recognize that breast cancer was not a local disease to be solved by more and more extensive local therapy.

He also challenged us to think about prevention. That's an insight that came from those early studies when they realized that hormone therapy also reduced contralateral breast cancers, as well as distant recurrence and overall survival. That's why we're here today.

Bernie certainly did not work in isolation. He was joined by equally smart and passionate medical oncologists. He was clearly bolstered by statisticians who recognized the need for much larger clinical trials to be appropriately powered in order to find clinically relevant differences on which we could build.

But all of those people needed Bernie. We were all so much the richer for having known him, and for having benefited from his wisdom, passion, determination, and smarts.

Please take a moment to remember Bernie. Look around and see all of the things that wouldn't be here today or would have taken longer to get here had we not had Bernie as one of our early champions.

Kathy D. Miller, MD, is associate director of clinical research and co-director of the breast cancer program at the Melvin and Bren Simon Cancer Center at Indiana University. Her career has combined both laboratory and clinical research in breast cancer.

Follow Medscape on Facebook, Twitter, Instagram, and YouTube

Read more:
Remembering Bernie: An Early Champion in Breast Cancer - Medscape

Recommendation and review posted by Bethany Smith

When it comes to finding an effective adult acne treatment, youve likely tried every lotion, potion, and serum out there. But it also helps to get to the root of the problem. In other words, to really treat your adult acne, you may need to understand what causes it in the first place.

Because, honestly, theres nothing more disappointing than waiting until your 20s to finally have clear skin and then learning the hard way that bad breakouts dont necessarily end when your teenage years do. Coming to terms with adult acne is difficultbut rest assured, youre not the only adult dealing with zits.

Knowing whats causing your pimples can help you clear up your skin and keep breakouts at bay. Keep reading to learn some of the most common adult acne causesand the best ways to treat these stubborn breakouts.

At the root of all acne is a clogged pore. Your pores, which are the opening that surrounds each hair follicle, are an important part of your skin because they also house your sebaceous glands.

These glands secrete sebum (oil) through the pore opening, which helps keep your skin soft and protected. But if the pore gets clogged by dirt, dead skin cells, excess oil, and possibly bacteria, youve got a recipe for a pimple.

Sometimes, just taking better care of your skin by cleansing or exfoliating regularly can be enough to prevent acne. For many others, though, the situation is more complicated. And, especially when youre an adult, trying to figure out whats causing your acne can get pretty frustrating.

Fluctuation in hormones, such as before ones menstrual cycle, is the main cause, dermatologist Julia Tzu, M.D., of Wall Street Dermatology, tells SELF.

This issue usually rears its ugly head in the form of deep (painful) cystic acne around the chin, neck, and back, dermatologist Rebecca Kazin, M.D., of the Washington Institute of Dermatologic Laser Surgery and the Johns Hopkins Department of Dermatology, tells SELF.

Cysts are pockets of pus that form deep in the skin, SELF explained previously. Theyre notoriously stubborn to treat because topical treatments dont usually have much of an effect. And because theyre so deep, they are more likely to cause scarring if popped.

Because your hormones naturally fluctuate at certain points in your life, the American Academy of Dermatology (AAD) explains, hormone-related acne is most likely to pop up:

We know that chronic stress can play a huge role in skin issues like acne, and its strongly suspected that the hormone cortisol may be responsible for the link.

When youre stressed, your adrenal gland releases cortisol, Neal Schultz, M.D. a New York Citybased dermatologist, tells SELF, and recent research also suggests that its produced locally in hair follicles and different types of skin cells. Although its commonly referred to as the stress hormone, cortisol is actually an important compound that helps regulate a ton of different bodily processes, including the immune system, digestive system, and neurological systems affecting your mood. Its levels naturally fluctuate over time (even within a single day).

But when you experience stressespecially chronic stresscortisol can start working overtime, causing issues with those bodily processes, including messing with your skin. Research suggests it may contribute to acne by creating a favorable environment for bacteria-driven inflammatory acne.

You may not have considered the effect that your environment has on your skinespecially the dirt and UV radiation outside. Air pollution just puts this layer of crap on your face, Dr. Schultz says, especially if you live in a city.

However, experts still dont totally understand how pollution can contribute to acne. Obviously, having excess dirt and grime on your face can increase your chances of getting clogged pores, so removing that stuff via a consistent cleansing routine is definitely helpful. But can exposure to UV rays or chemicals in the air actually damage your skin? Or cause acne?

Well, we know that UV exposure increases your risk for skin cancer and premature signs of aging, like fine lines and dark spots. And its possible for sun exposure to cause acne because it dries out the skin, leading to excess oil production in an effort to compensate. Thats why its always important to wear a broad-spectrum sunscreen with at least 30 SPF basically every day. Itll help prevent adult acne and help protect your face in general.

If you have oily or combination skin and are prone to breakouts, you should be using skin-care products labeled oil-free, noncomedogenic, or water-based, Dr. Schultz says. Products like these are less likely to clog your pores.

Try a light or gel-based moisturizer like Simple Light Hydrating Moisturizer, $4; CeraVe Facial Moisturizing Lotion, $12; or Tatcha the Water Cream, $68.

Overwashing your face can make acne worse, Dr. Kazin explains. Although some people with especially dry or sensitive skin find that they only need to cleanse once a day, most of us should be cleansing twice a day with a gentle cleanser. Cleansing any more than that is usually too much and can just dry out skin, which can cause [it] to produce more oil to overcompensate, Dr. Kazin says.

Gentle cleansers like Cetaphil Gentle Skin Cleanser, $14; SkinCeuticals Gentle Cleanser, $35; or Dermalogica Ultracalming Cleanser, $62, wont aggravate your skin. Additionally, some people find that cleansing balms or oils like Biore Makeup Remover Cleansing Oil, $8; DHC Deep Cleansing Oil, $28; Boscia MakeUp-BreakUp Cool Cleansing Oil, $32; or Then I Met You Living Cleansing Balm, $38, remove makeup more effectively and help their skin feel more moisturized than traditional cleansers.

Additionally, exfoliating too often or with products that are too harsh can damage skin and exacerbate acne. The type of exfoliating you should be doing and how frequently you should be doing it (if at all) depends on your skin type and your major skin concerns. But in general, experts recommend going with the gentler chemical exfoliants (products containing ingredients like lactic acid, glycolic acid, or salicylic acid) over scrubs or brushes, which are considered manual or physical exfoliants.

Experts also recommend exfoliating no more than three times per week for most people. If you have more dry or sensitive skin, just exfoliating once a week or every other week may be plenty for you.

For gentle exfoliating products, check out Paulas Choice the Unscrub, $29; Tatcha the Rice Polish, $65; or Benton Aloe BHA Toner, $19.

Weve all heard that some ridiculously long list of foods like chocolate, fried foods, pizza, caffeine, or dairy can cause acne. But, Dr. Schultz says, theres no conclusive proof that our dietary choices make a huge difference in the severity of acne.

Still, everyones skin is different and some people really do notice that their skin reacts badly after they eat certain foods. So the guiding rule here is to pay attention to your skin, and if you feel like it helps to avoid certain foods, you can try to cut them out. That said, planning out any major dietary changesespecially ones involving eliminating foodsis something thats best done with the guidance of your doctor or an R.D., so consider chatting with your derm before swearing off dairy.

In some cases, adult acne could be a symptom of another health condition, the AAD says.

For instance, one common hormone-related condition that results in acne is polycystic ovary syndrome (PCOS), a condition that causes symptoms such as irregular periods, facial hair, and weight gain. But PCOS is also known to cause hormonal acne thanks to the abnormal hormonal fluctuations it can cause.

Additionally, medications such as corticosteroids, lithium, or androgens can cause acne as a side effect, the Mayo Clinic says. So if you have any conditions that are being managed with those drugs, youre more likely to get acne.

If you think your acne might be due to an underlying health issue or medication, its especially important to check in with a dermatologist to figure out whats actually going on.

If a close relative has dealt with adult acne, you may be predisposed to having it too, according to the AAD. Part of that is because some things about your skin have genetic factors, like the size and visibility of your pores.

These genetic factors may be out of your control, but you *can* change your skin-care regimen to make sure youre giving your skin the best chance. That means knowing your skin type and using products and steps that work with your skin, possibly with the help of a dermatologist and prescription acne treatments.

The first and most important thing to to do when tackling acne is to make sure you have an arsenal of products with science-backed ingredients at your disposal. Remember that not every product or ingredient is going to work for everyone, and many of these products need to be used consistently for a few weeks before theres any noticeable change in your skin. So take it slowbut be persistent. And if youre not seeing any results or you cant find products that dont irritate your skin, talk to a dermatologist for some guidance and, maybe, a prescription treatment.

Here are the ingredients to look for:

Salicylic acid is a beta-hydroxy-acid (BHA), a kind of chemical exfoliant. It works by dissolving the bonds between dead skin cells. Salicylic acid is also particularly helpful when treating acne because its oil-soluble, which allows it to work its unclogging magic deeper in your oily pores than other chemical exfoliants.

Find it in: A ton of over-the-counter cleansers, spot treatments, and masks. For most people, its gentle enough to use on your whole facepossibly even daily. To start with, try a salicylic acidcontaining cleanser like Neutrogena Oil-Free Acne Wash, $10, or Dermalogica Breakout Clearing Foaming Wash, $20. When youre ready for toners and serums, check out La Roche-Posay Effaclar Clarifying Solution Acne Toner With Salicylic Acid, $15; Paulas Choice 2% Skin Perfecting BHA Liquid Exfoliant, $30; or SkinCeuticals Blemish and Age Defense Serum $92.

Glycolic acid is an alpha-hydroxy acid (AHA), another type of chemical exfoliant.

Find it in: Cleansers, serums, and peels. Pay attention to the concentration of glycolic acid in a given product as this will clue you in to how strong it will be. As the concentration gets higher, the product will be more powerful, but also more sensitizing. So if youre a beginner, start at the lower end of the spectrum with products like Pixi Glow Tonic, $30; Mario Badescu Glycolic Acid Toner, $18; or First Aid Beauty Facial Radiance Pads, $32. If you want something stronger, check out The Ordinary Glycolic Acid 7% Toning Solution, $9, or Juice Beauty Green Apple Peel, $42.

Lactic acid is yet another chemical exfoliant, an AHA. But lactic acid is known to be gentler than other types of chemical exfoliants, so its a good place to start if youre new to exfoliating treatments.

Find it in: Lactic acid is often paired with other acids in serums, toners, and peels, which means you could still be exposed to a more intense acid without realizing. But you can find lactic acid on its own in The Ordinary Lactic Acid 5% + HA 2% Superficial Peeling Formulation, $7; PCA Skin Facial Wash, $33; and the cult-favorite Sunday Riley Good Genes All-in-One Lactic Acid Treatment, $158.

Polyhydroxy acids (PHAs), which includes gluconolactone and lactobionic acid, are another class of chemical exfoliants and are generally considered to be the most gentle. If you have very dry or sensitive skin, or youve had bad reactions to other chemical exfoliants in the past, you should consider using a PHA.

Find it in: Lots of exfoliating peels, masks, and creams, such as Dr. Jart Dermaclear Micro Milk Peel, $42; Glow Recipe Avocado Melt Sleeping Mask, $45; and Cosrx PHA Moisture Renewal Power Cream, $25.

Benzoyl peroxide works by actually killing the acne bacteria while exfoliating the pores at the same time. Its not as gentle as the chemical exfoliants, so be careful when using it and make sure to moisturize.

Find it in: A classic derm recommendation, PanOxyl facial wash, comes in both lower-strength and higher-strength versions. But benzoyl peroxide is also found in many lotions and spot treatments, often paired with a chemical exfoliant like salicylic acid. Check out SkinMedica Acne Treatment Lotion, $56; Glo Skin Beauty Clear Skin Spot Treatment, $26; and PCA Skin Acne Cream, $30.

Sulfur doesnt have as much research behind it for acne as some of the other options on this list, but it is often a recommended treatment for acne-like bumps related to rosacea.

Find it in: Mainly spot treatments and face masks, like Murad Clarifying Mask, $40; Peter Thomas Roth Sulfur Cooling Mask, $52; Sunday Riley Saturn Sulfur Acne Treatment Mask, $55; and First Aid Beauty Anti-Redness Serum, $36.

Azelaic acid is another rosacea/acne crossover medication thats great at clearing the bumps sometimes seen in rosacea as well as pimples. As SELF explained previously, the exact mechanism by which azelaic acid works isnt totally understood. But we do know its effective.

Find it in: Azelaic acid is available in a few prescription forms, but its also present in over-the-counter products at lower concentrations. For concentrated options, check out The Ordinary Azelaic Acid Suspension 10%, $8, and Paulas Choice 10% Azelaic Acid Booster, $36. But azelaic acid is also included alongside other acne-treating ingredients in Ren Ready Steady Glow Daily AHA Tonic, $35, and PCA Skin Acne Gel, $50.

Retinoids are vitamin A derivatives, including retinol, retinal (retinaldehyde), and retinoic acid. They come in over-the-counter options (usually the active ingredient is retinol in these) and stronger prescription versions. Topical retinoids are fortunately one of the most effective treatments for acne and also happen to be a highly effective anti-aging ingredient, Dr. Tzu notes.

The biggest downside is theyre harsh and can sometimes be too much for sensitive skin, especially when youre first starting to use them. Thats why its important to use them just a few days a week at first, to always moisturize effectively, and to be extremely diligent about wearing sunscreen when using a retinoid.

Find it in: Retinol is available in many over-the-counter products, and thats generally the best place to start, because retinoids can be irritating. There are really a ton of retinol products out there, so check out these dermatologist-recommended options. If you want to try something stronger, you can opt for Differin (adapalene), $29, which used to be prescription-only but is now available over-the-counter. For more severe or stubborn acne, talk to a dermatologist about getting a prescription retinoid.

Exfoliation is the most important thing you can do on a regular basis to be fighting acne both in terms of preventing it and treating it, Dr. Schultz says. Whether you choose to use a chemical or physical exfoliant, know that this step will help prevent breakouts by keeping your pores clear and helping to remove any clogs you currently have.

If your skin can handle it, glycolic acid is Dr. Schultzs go-to ingredient, and he suggests using leave-on products or masks rather than cleansers, which will only stay on your skin for a short amount of time.

That said, be careful not to exfoliate too often, which can result in irritated, flaky, dry skin. Between one and three times a week is plenty for most people, but your skin may be able to take more or less than that depending on your individual skin type and concerns.

Spot treatments are key for treating a pimple ASAP, especially ones containing benzoyl peroxide, which work by killing the bacteria thats often responsible for acne. It can be a little harsh, though, so those with sensitive skin should be careful with it.

Try this classic spot treatment: Neutrogena On-the-Spot Acne Treatment, which contains benzoyl peroxide, heavy-duty action.

As we mentioned, pimples form when a pore gets clogged with dirt, oil, and dead skin cells. If bacteria are also present, the pimple might get inflamed, meaning it becomes red, swollen, and painful. Not all pimples are inflamed, but those that are tend to be extra unpleasant to deal with. So finding ways to calm them down while treating the root of the problem is essential.

If you have inflamed acne, look for products that contain soothing ingredients (like colloidal oatmeal, aloe, or centella asiatica) alongside acne-fighting ingredients, like salicylic acid.

Depending on the root cause(s) and severity your acne, you may find that topical treatments dont cut it. For instance, hormonal acne is fueled by internal processes that cant really be tamed with external medications.

In that case, your dermatologist may recommend an oral medication. Medications that manipulate hormonal levels, such as oral contraceptives and spironolactone, are helpful in curbing hormonal chin and lower face outbreaks, Dr. Tzu says. Additionally, oral retinoids like isotretinoin (formerly Accutane) are considered the big dermatological guns when fighting acne. Ask your derm about what might work for you.

When it comes to cystic acne, topical treatments are unlikely to cut it. And because those big, painful zits are so deep in the skin, theyre more likely to leave a scar if you pick and prod at them than other types of acne. The only way to reduce it quickly is to drain it, and thats not a DIY deal, Dr. Schultz warns.

One option, if you have access to a dermatologist, is to get a cortisone shot to deal with a stubborn cyst. Cortisone shots are the true spot treatments for painful cystic acne lesions, Dr. Tzu says.

There are ways to deal with them at home, though, by applying a warm or cold compress (whichever feels better to you), applying a small amount of over-the-counter hydrocortisone cream to calm the inflammation, and just waiting it out.

Related:

Originally Appeared on Self

Here is the original post:
8 Causes of Adult Acneand How to Actually Treat It - Yahoo Lifestyle

Recommendation and review posted by Bethany Smith

Defeating severe obesity is healthy for moms and babies alike.

LOS ANGELES (PRWEB) November 01, 2019

An October 16 article on WebMD reported on a recent study finding that obese women who undergo weight loss surgery before becoming pregnant decrease health risks to themselves and their babies. Los Angeles-based weight loss surgery specialists Dr. Feiz and Associates says that the research demonstrates that defeating obesity with the help of a weight-loss procedure is an overall boon to a patients health as well as her offsprings.

The weight loss clinic says its no secret that when individuals struggling with obesity lose significant amounts of weight, their overall health and quality of life increases. Common conditions that are linked to obesity include type 2 diabetes, high blood pressure, and heart disease. The clinic adds that all of these conditions can not only shorten individuals life expectancy but also affect the quality in which they are able to live out those years. The problem, of course, is that defeating obesity is a lot easier said than done.

While natural weight loss through proper diet and exercise is theoretically a simple matter of consuming fewer calories than one burns, there are a number of reasons why bariatric surgery appears to be necessary for the large majority of patients to defeat severe obesity. Dr. Feiz and Associates says that one reason involves the reality that obese individuals tend to produce higher amounts of a hormone called ghrelin, which spurs our desire to eat. As dieters begin losing weight, however, it gets worse because the production of the hormone increases ever further the body is essentially preparing for a famine that is never going to come. The result is nagging feelings that are essentially identical to hunger and very difficult to ignore.

The clinic says that reducing ghrelin production is part of why such procedures as a sleeve gastrectomy have proven so powerful. The original premise of the procedure was simply to reduce the size of the stomach to make overeating uncomfortable and reduce the appetite. Over time, however, it became clear that removing roughly 75%-85% of the stomach also removes the area of the body that might be most responsible for ghrelin production. Thus, patients are discouraged from overeating while being less bothered by the feelings that make them want to overeat in the first place.

Dr. Feiz and Associates note that its crucial for prospective patients to realize that undergoing a weight loss procedure will not automatically fix all of their weight-related health issues and they still have to work at changing their relationship with food. The clinic says that with the aid of a weight loss procedure, however, reducing significant amounts of weight through diet becomes much easier to accomplish.

Readers who would like to learn more about Dr. Feiz and Associates and their weight loss services can call 310-855-8058 or visit the clinics website at https://www.drfeiz.com.

Share article on social media or email:

More here:
Weight Loss Surgery Benefits by Bolstered by Research into Bariatric Procedures and Childbirth, Says Dr. Feiz and Associates - PR Web

Recommendation and review posted by Bethany Smith